Presbia (LENSF) 10-K 12 Apr 19 2018 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2018	Apr. 12, 2019	Jun. 30, 2018
Document And Entity Information [Abstract]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2018
Document Fiscal Year Focus	2018
Document Fiscal Period Focus	FY
Trading Symbol	LENS
Entity Registrant Name	PRESBIA PLC
Entity Central Index Key	0001591096
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	true
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		17,229,624
Entity Public Float			$ 13,158,204

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Current assets
Cash	$ 2,527	$ 3,236
Accounts receivable	20	8
Inventory	59	127
Prepaid expenses and other current assets	175	108
Total current assets	2,781	3,479
Property and equipment, net	367	477
Intangible assets	1,344	1,479
Other assets	38	127
Total assets	4,530	5,562
Current liabilities
Accounts payable	605	628
Due to related parties	39	23
Note payable, current portion		480
Secured debt with related party, current portion	20
Other current liabilities	301	1,151
Total current liabilities	965	2,282
Secured debt with related party, net of unamortized transaction costs ($1,585)	1,915
Deferred rent	85	107
Due to related parties, net of current portion		12
Other liabilities, net of current portion	21	30
Total liabilities	2,986	2,431
Commitments and contingencies (note 12)
Shareholders' equity
Deferred ordinary shares € 1.00 (US$1.35) par value, 39,994 shares authorized, issued and outstanding at December 31, 2018 and 2017	54	54
Additional paid-in capital	98,235	91,362
Accumulated deficit	(96,762)	(88,302)
Total shareholders' equity	1,544	3,131
Total liabilities and shareholders’ equity	4,530	5,562
Series 2 Redeemable Preferred Shares [Member]
Shareholders' equity
Preferred shares
USA Preferred Shares [Member]
Shareholders' equity
Preferred shares
Ordinary Shares [Member]
Shareholders' equity
Ordinary Shares	$ 17	$ 17

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) $ in Thousands	Dec. 31, 2018USD ($)$ / sharesshares	Dec. 31, 2017$ / sharesshares	Dec. 31, 2017€ / sharesshares
Unamortized transaction costs | $	$ (1,585)
Preferred shares, par value | $ / shares	$ 0.001
Preferred shares, shares authorized	50,000,000
Ordinary shares, par value | $ / shares	$ 0.001
Ordinary shares, shares authorized	350,000,000
Deferred ordinary shares, par value | (per share)	$ 1.35	$ 1.35	€ 1
Deferred ordinary shares, shares authorized	39,994	39,994	39,994
Deferred ordinary shares, shares issued	39,994	39,994	39,994
Deferred ordinary shares, shares outstanding	39,994	39,994	39,994
Series 2 Redeemable Preferred Shares [Member]
Preferred shares, par value | $ / shares	$ 0.001	$ 0.001
Preferred shares, shares authorized	50,000,000	50,000,000	50,000,000
Preferred shares, shares issued	100	0	0
Preferred shares, shares outstanding	100	0	0
USA Preferred Shares [Member]
Preferred shares, par value | $ / shares	$ 0.01	$ 0.01
Preferred shares, shares authorized	8,000	8,000	8,000
Preferred shares, shares issued	5,239	0	0
Preferred shares, shares outstanding	5,239	0	0
Ordinary Shares [Member]
Ordinary shares, par value | $ / shares	$ 0.001	$ 0.001
Ordinary shares, shares authorized	350,000,000	350,000,000	350,000,000
Ordinary shares, shares issued	17,157,160	17,121,857	17,121,857
Ordinary shares, shares outstanding	17,157,160	17,121,857	17,121,857
USA Common Stock [Member]
Ordinary shares, par value | $ / shares	$ 0.01	$ 0.01
Ordinary shares, shares authorized	5,000	5,000	5,000
Ordinary shares, shares issued	2,000	2,000	2,000
Ordinary shares, shares outstanding	2,000	2,000	2,000

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Income Statement [Abstract]
Revenues	$ 21	$ 14
Type of Revenue [Extensible List]	us-gaap:ProductMember	us-gaap:ProductMember
Cost of goods sold	$ 51	$ 97
Type of Cost, Good or Service [Extensible List]	us-gaap:ProductMember	us-gaap:ProductMember
Gross loss	$ (30)	$ (83)
Operating expenses:
Research and development	3,529	7,074
Sales and marketing	1,349	3,278
General and administrative	3,645	6,280
Total operating expenses	8,523	16,632
Operating loss	(8,553)	(16,715)
Interest expense, net	87	37
Other expense	10	1
Loss before income tax	(8,650)	(16,753)
Income tax provision (benefit)	(235)	245
Net loss	(8,415)	(16,998)
USA new preferred shares dividends	45
Net loss attributed to common stock - basic and diluted	$ (8,460)	$ (16,998)
Net loss per share - basic and diluted	$ (0.50)	$ (1.04)
Weighted average, shares outstanding - basic and diluted	17,077,817	16,298,505

Consolidated Statement of Chang

Consolidated Statement of Changes in Shareholders' Equity - USD ($) $ in Thousands	Total	Series 1 Preferred Shares and USA Preferred Shares [Member]	Series 2 Redeemable Preferred Shares and USA New Preferred Shares [Member]	Warrant Covering 1,953,125 Ordinary Shares [Member]	Warrant Covering 14,731,667 Ordinary Shares [Member]	Series 1 Preferred Shares [Member]	Preferred Stock [Member]	Preferred Stock [Member]Series 1 Preferred Shares and USA Preferred Shares [Member]	Preferred Stock [Member]Series 2 Redeemable Preferred Shares and USA New Preferred Shares [Member]	Preferred Stock [Member]Series 1 Preferred Shares [Member]	Ordinary Shares [Member]	Deferred Shares [Member]	Additional Paid-In Capital [Member]	Additional Paid-In Capital [Member]Series 1 Preferred Shares and USA Preferred Shares [Member]	Additional Paid-In Capital [Member]Series 2 Redeemable Preferred Shares and USA New Preferred Shares [Member]	Additional Paid-In Capital [Member]Warrant Covering 1,953,125 Ordinary Shares [Member]	Additional Paid-In Capital [Member]Warrant Covering 14,731,667 Ordinary Shares [Member]	Additional Paid-In Capital [Member]Series 1 Preferred Shares [Member]	Accumulated Deficit [Member]
Balance at Dec. 31, 2016	$ 8,439										$ 13	$ 54	$ 79,676						$ (71,304)
Balance, shares at Dec. 31, 2016											13,420,927	39,994
Proceeds from issuance of ordinary shares, preferred shares and warrants, net of costs	10,534										$ 4		10,530
Proceeds from issuance of ordinary shares, preferred shares and warrants, net of costs, shares											3,611,764
Stock-based compensation	1,156												1,156
Issuance of restricted stock, shares											89,166
Net loss	(16,998)																		(16,998)
Balance at Dec. 31, 2017	3,131										$ 17	$ 54	91,362						(88,302)
Balance, shares at Dec. 31, 2017											17,121,857	39,994
Proceeds from issuance of ordinary shares, preferred shares and warrants, net of costs			$ 2,053	$ 2,837	$ 1,395	$ 2,053									$ 2,053	$ 2,837	$ 1,395	$ 2,053
Proceeds from issuance of ordinary shares, preferred shares and warrants, net of costs, shares									5,339	5,000
Exchange of PLC Series 1 Preferred Shares and USA Preferred Shares for PLC Series 2 redeemable preferred shares and USA new preferred shares		$ (2,053)												$ (2,053)
Exchange of PLC Series 1 Preferred Shares and USA Preferred Shares for PLC Series 2 redeemable preferred shares and USA new preferred shares, shares								(5,000)
USA new preferred shares dividends	(45)												45						(45)
Stock-based compensation	543												543
Issuance of restricted stock, shares											35,303
Net loss	(8,415)																		(8,415)
Balance at Dec. 31, 2018	$ 1,544										$ 17	$ 54	$ 98,235						$ (96,762)
Balance, shares at Dec. 31, 2018							5,339				17,157,160	39,994

Consolidated Statement of Cha_2

Consolidated Statement of Changes in Shareholders' Equity (Parenthetical) - shares	Dec. 31, 2018	Dec. 10, 2018	Apr. 12, 2018
Number of ordinary shares covered by warrants		14,731,667	1,953,125
Warrant Covering 1,953,125 Ordinary Shares [Member]
Number of ordinary shares covered by warrants	1,953,125
Warrant Covering 14,731,667 Ordinary Shares [Member]
Number of ordinary shares covered by warrants	14,731,667

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Cash flow from operating activities:
Net loss	$ (8,415)	$ (16,998)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	244	477
Inventory provisions	45	90
Loss on disposal of fixed assets	10	1
Stock-based compensation	530	1,168
Imputed interest expense	38	83
Changes in operating assets and liabilities:
Accounts receivable	(13)	(5)
Inventory	23	85
Prepaid expenses and other current assets	(67)	286
Other assets	89	(1)
Accounts payable and other current liabilities	(557)	528
Income taxes payable	(281)	231
Deferred rent	(22)	79
Due to related parties	17	5
Net cash used in operating activities	(8,359)	(13,971)
Cash flow from investing activities:
Purchase of intangible assets		(125)
Purchases of property and equipment	(4)	(73)
Net cash used in investing activities	(4)	(198)
Cash flow from financing activities:
Proceeds from issuance of ordinary shares from rights offering, net of costs		10,534
Proceeds from sale of preferred shares, net of costs	4,890
Proceeds from secured debt with related party, net of costs	3,284
Net cash provided by financing activities	7,667	10,024
Net decrease in cash	(696)	(4,145)
Effects of exchange rate on cash	(13)	48
Cash balance at beginning of period	3,236	7,333
Cash balance at end of period	2,527	3,236
Supplemental disclosure of cash flow information:
Cash paid for income taxes	85	19
Supplemental disclosures of non-cash investing and financing activities:
USA new preferred shares dividends	45
Capitalized intangible asset costs included in accounts payable		15
Extinguishment of PLC Series 1 preferred shares, USA preferred shares and accrued dividends	(2,053)
Issuance of PLC Series 2 preferred shares, and USA New preferred shares	2,053
Warrant Covering 1,953,125 Ordinary Shares [Member]
Supplemental disclosures of non-cash investing and financing activities:
Issuance of a warrant covering ordinary shares	2,837
Warrant Covering 14,731,667 Ordinary Shares [Member]
Supplemental disclosures of non-cash investing and financing activities:
Issuance of a warrant covering ordinary shares	3,522
Note Payable To Neoptics A.G. [Member]
Cash flow from financing activities:
Payment of note payable to Neoptics A.G.	$ (507)	$ (510)

Consolidated Statements of Ca_2

Consolidated Statements of Cash Flows (Parenthetical) - shares	Dec. 31, 2018	Dec. 10, 2018	Apr. 12, 2018
Number of ordinary shares covered by warrants		14,731,667	1,953,125
Warrant Covering 1,953,125 Ordinary Shares [Member]
Number of ordinary shares covered by warrants	1,953,125
Warrant Covering 14,731,667 Ordinary Shares [Member]
Number of ordinary shares covered by warrants	14,731,667

Basis of Presentation and Descr

Basis of Presentation and Description of the Business	12 Months Ended
	Dec. 31, 2018
Accounting Policies [Abstract]
Basis of Presentation and Description of the Business	(1) Basis of Presentation and Description of the Business Presbia PLC (the “Company” or “Presbia PLC”), an Irish public limited company, was formed on February 6, 2014 through the issuance of 40,000 shares of €1.00 each for 40,000 Euro (approximately $54,000) for the purpose of consummating an initial public offering (“IPO”) of its ordinary shares. Presbia PLC’s ultimate controlling shareholder, Presbia Holdings (the “Parent”), was organized in the Cayman Islands in 2007 as an exempted company with limited liability. On October 21, 2013, the Parent completed a restructuring (the “2013 Restructuring”) which involved the formation on September 13, 2013 of an interim holding company, Presbia Ireland, Limited, and the contribution by the Parent of 100% of its direct and indirect ownership interests in its business, assets and subsidiaries to Presbia Ireland, Limited. On November 30, 2014, Presbia Holdings converted all the remaining indebtedness owed to Presbia Holdings by certain subsidiaries of Presbia Ireland, Limited at that time to equity (the “2014 Debt Conversion”). In the 2014 Debt Conversion, approximately $23.5 million of outstanding intercompany debt owed to Presbia Holdings was converted to equity of Presbia Ireland, Limited. On January 14, 2015, Presbia Holdings converted all the remaining indebtedness owed to Presbia Holdings by a subsidiary of Presbia Ireland, Limited at that time to equity (the “2015 Debt Conversion”) in the amount of approximately $1.6 million. On January 14, 2015, the Parent contributed all the share capital in issue in Presbia Ireland, Limited to Presbia PLC (the “2015 Capital Contribution”) in exchange for 9,166,667 ordinary shares of US$0.01 each of Presbia PLC. The aggregate 9,166,667 ordinary shares of Presbia PLC have been reflected as issued and outstanding as of the earliest date of the periods presented for purposes of computation of basic and diluted net loss per share. On February 3, 2015, Presbia PLC completed its initial public offering (“IPO”) of 4,166,667 of its ordinary shares at a price to the public of $10.00 per ordinary share and commenced trading on The Nasdaq Global Market under the symbol LENS. The Parent acquired 500,000 ordinary shares from the public offering. The net proceeds from the IPO consisted of aggregate gross proceeds of approximately $41.7 million less underwriting discounts and commissions of approximately $2.9 million and other issuance costs of approximately $2.0 million resulting in net proceeds of approximately $36.8 million. On August 3, 2015, Presbia Holdings completed the distribution of its holdings of 9,666,667 ordinary shares of Presbia PLC to its ordinary shareholders for the purpose of dissolving Presbia Holdings on November 25, 2015 and ceasing to be the Parent of Presbia PLC. On April 12, 2018, the Company and its wholly-owned subsidiary, Presbia USA, Inc. and Richard Ressler, one of the Company’s directors and its controlling shareholder, entered into a Stock Purchase Agreement pursuant to which Mr. Ressler acquired 100 preferred shares of Presbia PLC stock and 4,900 preferred shares of Presbia USA, Inc. stock for an aggregate price of $5.0 million, less legal and professional fees of $0.1 million, resulting in net proceeds of approximately $4.9 million. As part of this transaction, Mr. Ressler also acquired a warrant to purchase 1,953,125 ordinary shares of Presbia PLC at an exercise price of $2.56 per share. In a financing transaction that closed on December 10, 2018, the Company and its wholly-owned subsidiary, Presbia USA, Inc., entered into and closed a Securities Purchase and Exchange Agreement with Mr. Ressler. Under the terms of the agreement, Mr. Ressler provided a secured loan in the aggregate principal amount of $3.5 million less legal and professional fees of $0.2 million, resulting in net proceeds of approximately $3.3 million. He also exchanged all 4,900 preferred shares of Presbia USA, Inc. stock and 339 preferred shares dividends of Presbia USA, Inc. for 5,239 newly-designated Presbia USA New Preferred Stock, and he was issued a warrant to purchase 14,731,667 ordinary shares of Presbia PLC. Prior to the consummation of the December 10, 2018 transaction, Presbia PLC was the direct parent of Presbia Ireland, Limited (and Presbia Ireland, Limited was a direct subsidiary of Presbia PLC). The Companies effectuated a restructuring on December 10, 2018, which resulted in the inversion of the parent-subsidiary hierarchy of Presbia Ireland, Limited and Presbia USA, such that, following consummation of the restructuring transaction (i) Presbia PLC became the direct parent of Presbia USA (with Presbia USA being a direct subsidiary of Presbia PLC), and (ii) Presbia USA became the direct parent of Presbia Ireland, Limited. The accompanying consolidated financial statements have been derived from the historical cost basis of the assets and liabilities, financial condition and cash flows of Presbia PLC, organized in Ireland, Presbia Investments organized in the Cayman Islands, Presbia USA, Inc., organized in the United States and its subsidiaries, PresbiBio LLC and PresbiBio, LLC, Visitome, Inc. and Presbia Technologies, LLC, which are organized in the United States, and Presbia Ireland, Limited, organized in Ireland, and its subsidiaries, Presbia Deutchland, GmbH, organized in Germany, OPL, LLC , organized in the United States, and its direct and indirect subsidiaries, PIP Holdings, C.V and Presbia Cooperatief U.A., both organized in the Netherlands, and PresbiOptical LLC, organized in the United States (collectively, including Presbia PLC, the “Company”). Visitome, Inc. was liquidated in February 2019. Presbia Investments and Presbia Cooperatief U.A. are currently under liquidation proceedings in an effort to simplify the Company’s organizational structure. The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America. The Company’s fiscal year ends on December 31. The entities presented in the consolidated financial statements have been under common control during the periods presented. All intercompany accounts have been eliminated in consolidation. All amounts are shown in U.S. dollars. The Company, which began to be formed on June 29, 2007, has developed and is marketing a surgical solution to the age-related vision condition known as presbyopia. The Company’s primary objectives have been twofold: (1) achieve commercial success in those parts of the world where the Company’s surgical procedure has been approved by regulatory agencies and (2) successfully apply to the United States Food and Drug Administration (the “FDA”) for the authorization to market and manufacture the surgical procedure in the United States. Other than the FDA clinical trials that begun in 2014 and will continue to at least 2019, this procedure is currently not authorized by the FDA and may not be manufactured, sold, distributed or surgically performed on any individual in the United States. The Company’s principal revenue generating activity is the sale of the Company’s microlens to approved ophthalmologist physicians who, in turn, perform the surgical procedure on their patient base. Presbia is authorized to sell, market and perform this procedure in 40 countries through its wholly-owned Irish subsidiary, Presbia Ireland, Limited. Activities to-date have consisted primarily of research and development and expansion of its commercial activities in selected markets outside the United States. Going Concern Uncertainty At December 31, 2018, the Company has an accumulated deficit of $96.8 million and it expects to incur additional operating losses through 2019, and possibly further. As it continues to incur losses, the Company’s transition to profitability will depend on the successful development, approval and commercialization of its microlens. The Company may never achieve profitability, and unless and until it does, it will need to continue to raise additional capital. Based on the Company’s current business plan, management believes that its cash at December 31, 2018, will not be sufficient to meet its anticipated cash requirements during the twelve-month period subsequent to the issuance of the financial statements included in this Annual Report on Form 10-K. These factors raise substantial doubt about the Company’s ability to continue as a going concern within one year from the date this Annual Report on Form 10-K is filed with the U.S. Securities and Exchange Commission (SEC). The Company’s current commercialization strategy is targeted to countries where the Company can establish the market for its technology. This commercialization strategy will undergo continual prioritization and in the future the Company may adjust its commercialization efforts to preserve its existing cash or realize better results than anticipated which could have a positive impact on cash. The Company’s U.S. pivotal clinical trial and planned FDA approval is its highest priority. The Company must raise additional capital to fund its operations. It may raise additional capital through equity offerings, debt financings, collaborations and/or licensing arrangements. Additional funds may not be available when the Company needs them on terms that are acceptable to the Company, or at all. If adequate funds are not available on acceptable terms, the Company may be required to delay, reduce the scope of, or curtail, its operations. To the extent that the Company raises additional funds by issuing equity securities, its shareholders will experience dilution, and debt financing, if available, may involve restrictive covenants.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2018
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	(2) Summary of Significant Accounting Policies Use of Estimates The preparation of the Company’s consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires that management makes estimates and assumptions that are included in the consolidated financial statements and accompanying notes. The actual results may differ from those estimates. Segment Information In accordance with Accounting Standard Codification (“ASC”) 280-10-50, Segment Reporting Foreign Currency The functional currency of subsidiaries outside the United States of America is the U.S. Dollar. Transactions in foreign currencies during the year are re-measured at rates of exchange on the dates of the transactions. Gains and losses related to re-measurement of items arising through operating activities are accounted for in the statement of operations and comprehensive loss and included in general and administrative expense. Aggregate foreign exchange loss was $12,000 and $59,000 for the years ended December 31, 2018 and 2017, respectively. Reclassifications Certain prior year balances within the consolidated financial statements have been classified to conform to current year presentation. Concentrations of Credit Risk Cash is generally deposited in demand deposit accounts that, from time to time, may exceed insurable limits. The Company has not experienced any losses from its deposits of cash. Fair Value of Financial Instruments The carrying values of certain of the Company’s financial instruments, such as prepaid expenses, accounts payable and accrued expenses, approximate fair value due to their short maturities. The Company’s debt obligation approximates fair value as a result of imputed interest which approximates prevailing market rates. Amounts payable to related parties, including the payable due to the Parent, which has no fixed maturity or expiration date, do not have readily determinable fair values. Cash The Company considers highly liquid investments with original maturities less than 90 days to be cash equivalents. As of December 31, 2018 and 2017, the Company had no such short-term investment instruments and maintained its cash in bank demand deposit accounts. Inventory The Company accounts for inventory at the lower of cost and net realizable value. Inventory is stated at weighted average cost, which is determined by applying the current average cost to the ending inventory. Inventory consists of lenses and lens inserters and other accessories used by physicians in the surgical process associated with the lenses. The Company maintains serialized records of all lenses, including the five-year expiration date of each lens, after which the lens cannot be sold. The Company considers the expiration dates of lenses, in addition to comparing the carrying amount of inventory to expected demand, and will write-down inventory for amounts determined to be excess or obsolete. Property and Equipment Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation of property and equipment is computed using the straight-line method over their estimated useful lives of three to ten years. Leasehold improvements are amortized over the lesser of the useful life of the asset or the remaining term of the lease. Repairs and maintenance of property and equipment are expensed as incurred. Upon retirement or sale, the original cost and accumulated depreciation are removed and any gain or loss is recognized in the consolidated statements of operations and comprehensive loss. Impairment of Long-Lived Assets The Company reviews the recoverability of long-lived and finite-lived intangible assets when circumstances indicate that the carrying amount of assets might not be recoverable. This evaluation is based on various analyses, including undiscounted cash flow projections. In the event undiscounted cash flow projections indicate impairment, the Company would record an impairment based on the fair value of the assets at the date of the impairment. Intangible Assets On August 2, 2016, Presbia Ireland, Limited, a wholly-owned subsidiary of the Company, entered into an asset purchase agreement (the “Agreement”) with Neoptics AG (“Neoptics”) pursuant to which the Company acquired certain assets from Neoptics for an aggregate purchase price of 1.5 million Swiss Francs (approximately $1.5 million based on the exchange rate between the Swiss Franc and the U.S. Dollar on August 2, 2016) payable in three equal installments on each of August 2, 2016, December 31, 2017 and December 31, 2018. The assets acquired include patents, pending patents, and other immaterial assets. Effective August 2, 2016, the Company became responsible for all expenses associated with such assets. Pursuant to the terms of the Agreement, the acquisition closed on August 2, 2016. Substantially all of the fair value of the gross assets acquired is concentrated in the acquired intellectual property rights or patents and not in the trademarks, documents or electronic data obtained from the Seller. The Company determined the intellectual property right or patents were akin to inputs within the scope of ASC 805 “Business Combinations” and that no substantive processes were acquired in the assets acquisition. Therefore, the Company applied the asset acquisition accounting guidance in ASC 805-50-30 “ Initial Measurement of Acquisition of Assets Rather than a Business The Company made a final payment of $0.5 million in cash in exchange for these patents and patent applications in the year ended December 31, 2018. The useful life of the patents was determined to be 12 years and 4 months and will be amortized through November 25, 2028. The Company recorded amortization expense of approximately $136,000 with net carrying amount of approximately $1,344,000 as of December 31, 2018. For fiscal years 2019 to 2022, approximately $135,000 will be recorded annually as amortization expense for the Neoptics assets. The Company reviews its long-lived intangible assets for impairment at least annually or more frequently if impairment indicators arise. In evaluating the potential for impairment of the Neoptics assets, we make assumption regarding future operating performance, business trends and future useful life of these assets. As a result of these evaluations, the Company did not recognize impairment charges for the years ended December 31, 2018 and 2017, as it believes that the carrying value of these assets do not exceed their fair value. Costs incurred to develop software for the Company’s website are capitalized and amortized over the estimated useful life of the software and are included in intangible assets. Costs related to design or maintenance of website development is expensed as incurred. For the years ended December 31, 2018 and 2017, there were no capitalized costs associated with website development. Amortization expense of $1,000 and $15,000 was recorded the years ended December 31, 2018 and 2017, respectively. Net Loss per Common Share Basic net loss per ordinary share is calculated by dividing net loss, as adjusted for dividends on the USA New Preferred Shares in the period, by the weighted average number of ordinary shares outstanding during the reporting period, less unvested restricted stock awards. Diluted net loss allocated to ordinary shareholders per share is calculated based on the weighted average number of ordinary shares and dilutive potential ordinary shares outstanding during the period. Dilutive potential ordinary shares consist of the shares issuable upon the exercise of stock options and warrants, and upon the vesting of restricted shares under the treasury stock method. In net loss periods, basic and diluted net loss per share are identical since the effect of potential ordinary shares is anti-dilutive and therefore excluded. Basic and diluted net loss per share were calculated as follows (in thousands, except share and per share data): December 31, 2018 2017 Net Loss $ (8,415 ) $ (16,998 ) USA new preferred shares dividends $ 45 $ - Net loss attributable to common shareholders $ (8,460 ) $ (16,998 ) Weighted average shares outstanding – basic and diluted 17,077,817 16,298,505 Basic and diluted net loss per share $ (0.50 ) $ (1.04 ) The following potentially dilutive securities were excluded from the computation of diluted weighted average shares outstanding because their inclusion would have been antidilutive: December 31, 2018 2017 Options to purchase common stock 1,129,324 1,037,964 Restricted shares 49,189 — Warrant to purchase common stock (1)(2) 16,684,792 — Series 2 Redeemable Preferred Shares and USA New Preferred Shares outstanding 5,339 — Total potentially dilutive securities excluded from denominator of the diluted earnings per share Computation 17,868,719 1,037,964 (1) Includes 1,953,125 warrants to purchase ordinary shares of Presbia PLC at a price of US$2.56 per ordinary share, granted April 12, 2018 (see Note 8). (2) Includes 14,731,667 warrants to purchase ordinary shares of Presbia PLC at a price of US$0.60 per ordinary share, granted December 10, 2018 (see Note 8). Revenue Recognition Prior to 2018, we recognized revenue when there was persuasive evidence that an arrangement existed with our customers, selling prices were fixed or determinable, title or risk of loss had passed, and collection was reasonably assured. Revenue was recognized upon shipment and payments were either received in advance, or net 30 days for lenses or net 14 days for accessories. Distributor arrangements included certain perfunctory acceptance provisions and a one-year warranty, from the date of shipment, that products are free from defects in material workmanship. Under such provisions customers may reject shipments via written notifications ranging from 14-45 days or exchange defective product under warranty for the same non-defective product. We have not had any significant rejected shipments or warranty claims. We did not grant price concessions to our distributors. Effective January 1, 2018, the Company adopted the provisions of Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 606, Revenue from Contracts with Customers (“ASC 606”), using the modified retrospective transition method. Under this method, the Company recognizes revenue based on an analysis of the goods and services provided to our customers in the ordinary course. We analyze all commercial agreements to identify (i) contracts and arrangements with customers that meet the criteria for revenue recognition under the new standard (ii) identify all performance obligations under the contractual arrangement, such as the delivery of our Microlens to our customers and any other deliverable(s) as defined in a commercial arrangement (iii) the determination of the transaction price, (iv) the allocation of such pricing over the defined contractual obligations in the contract with the customer and (v) the recognition of revenue once the customer has assumed control over the contractual obligations. Control refers to the ability on the part of the customer to obtain substantially all the benefits of possession of the delivered product or service. The Company is required by ASC 606 to disaggregate revenue into categories that depict the nature, amount, timing, and uncertainty of revenue and cash flows as affected by economic factors. Currently, the Company believes these economic factors are primarily attributable to different geographic regions, under one operating segment. Refer to Note 11, Operating Segments and Geographic Information, to the Company’s consolidated financial statements for additional details of revenues by geographic region. In the future, the Company will reassess whether geographic region revenue disaggregation continues to depict the nature, amount, timing, and uncertainty of revenue and cash flows as affected by economic factors. Future assessment may be affected by, but not limited to: (i) an increase in revenue; (ii) concentration of customers; and (iii) other economic factors, in accordance with ASC 606. In the years ended December 31, 2018 and 2017 there were five and four customers, respectively, that represented 100% of total sales recognized for each year. As of December 31, 2018, the Company was not authorized to manufacture or sell any of its products or services within the United States and, as a result, all of the Company’s revenues are derived from foreign customers. The Company recognized revenues of $21,000 and $14,000 from foreign ophthalmic clinics during the years ended December 31, 2018 and 2017, respectively. Clinical Trials In February 2015, the Company received approval from the FDA to commence enrollment of the second stage of its U.S. staged pivotal clinical trial of its Microlens involving the implantation of presbyopic patients. Enrollment for the second stage was completed in September 2015. The first staged-enrollment commenced during the first quarter of 2014, and during these trials, the Company incurred costs for patient recruiting, acquisition of clinical test equipment to be used in the trials, outside experts to read and interpret the results of the studies, third party costs to monitor the investigational sites and perform data collection activities and surgeon and patient fees in connection with the surgical procedures and follow-up visits. The Company’s policy with respect to the recognition of these costs is to record such costs as research and development expense in the consolidated statements of operations and comprehensive loss in the period in which the services are provided. The Company will evaluate the purchases of clinical test equipment, on a case by case basis, to determine if there exists an alternative use for the equipment following the clinical trials. In the event that the Company determines that there is no alternative use for the test equipment, that cost will be expensed as part of research and development expense. Stock-Based Compensation The compensation cost of stock-based awards granted to employees is measured at grant date, based on the estimated fair value of the award. The Company estimates the fair value of stock options using a Black-Scholes option pricing model. Restricted stock units awarded to employees in 2018 include a performance provision as well as a provision that the recipient must be employed as conditions of vesting. The fair value of restricted stock units issued prior to 2018 was determined using a Monte Carlo Simulation, or “MCS”, methodology, which considers the separate probabilities that of the price thresholds or market conditions will be achieved under the Restricted Stock Units Plan guidelines. Compensation expense for options granted to non-employees is determined as the fair value of consideration received or the fair value of the equity instruments issued, whichever is more reliably measured. Stock-based compensation costs are expensed on a straight-line basis over the service period. The fair value of awards granted to non-employees is remeasured each period until the related service is complete or there exists a significant disincentive not to perform the required services. Stock-based compensation costs are reflected in the accompanying statements of operations and comprehensive loss based upon the underlying employees’ roles within the Company. Deferred Offering Costs Generally, costs incurred such as legal, accounting and other professional fees including printing costs in the course of preparing for a capital raise are deferred on the balance sheet as deferred offering costs, which are eventually reclassified when the capital raise is concluded as a reduction of the proceeds of the capital raise as part of additional paid in capital. On December 5, 2016, the Company filed with the SEC a Form S-1 Registration Statement under the Securities Act of 1933 for the purpose of distributing to holders of the Company’s ordinary shares, non-transferable and non-tradeable subscription rights to purchase ordinary shares (“rights offering”). During the years ended December 31, 2018 and 2017, the Company incurred approximately $0 million and $0.3 million related to its rights offering, respectively, which was completed on March 8, 2017. Upon completion of the rights offering, the Company netted approximately $0.3 million in offering costs against the gross proceeds in shareholders’ equity as of December 31, 2017. Income Taxes As described in Note 1, the Parent completed a restructuring on October 21, 2013. As a result, some of the entities are no longer pass-through entities or were restructured as taxable entities. Provisions for federal, foreign, state, and local income taxes are calculated on pre-tax income based on current tax law and include the cumulative effect of any changes in tax rates from those used previously in determining deferred tax assets and liabilities. Deferred income tax assets and liabilities are recorded for the expected future tax consequences of temporary differences between the financial statement carrying amounts and the income tax basis of assets and liabilities. A valuation allowance is recorded to reduce net deferred income tax assets to amounts that are more likely than not to be realized. Advertising Costs The Company incurs direct response advertising expense outside the United States in order to create awareness of the Company’s Microlens solution to presbyopia. The Company’s policy with respect to direct response advertising is to defer costs related to media and setup costs and amortize those costs to the consolidated statements of operations and comprehensive loss in the period in which the related revenue is recognized. Due to the early stages of market development and the uncertainty around the impact of advertising campaigns to-date, the Company expensed approximately $104,000, and $395,000 as part of sales and marketing expense in the consolidated statements of operations and comprehensive loss for the years ended December 31, 2018 and 2017, respectively. Risks and Uncertainties The Company’s product requires the approval of the FDA and regulatory agencies in the countries where the Company operates or expects to establish operations in the future. There is no assurance that the Company’s Future Accounting Pronouncements In February 2016, the FASB issued Accounting Standards Update (“ASU”) Leases (Topic 842) In February 2018, the FASB issued ASU Income Statement—Reporting Comprehensive Income (Topic 220)—Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income. In June 2018, the FASB issued ASU No. 2018-07, Compensation — Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting Recent Accounting Standards In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606). The new standard is based on the principle that revenue should be recognized to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. Topic 606 became effective for the Company in the first quarter of 2018 and allowed for full retrospective or a modified retrospective adoption approach. The Company adopted this new standard using the modified retrospective transition method In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows, which clarifies the classification of certain cash receipts and payments. The specific cash flow issues addressed by ASU 2016-15, with the objective of reducing the existing diversity in practice, are as follows: (1) Debt prepayment or debt extinguishment costs; (2) Settlement of zero-coupon debt instruments or other debt instruments with insignificant coupon interest rates; (3) Contingent consideration payments made after a business combination; (4) Proceeds from the settlement of insurance claims; (5) Proceeds from the settlement of corporate-owned life insurance policies; (6) Distributions received from equity method investees; (7) Beneficial interest in securitization transactions; and (8) Separately identifiable cash flows and application of the predominance in principle. ASU 2016-15 became effective for fiscal years beginning after December 15, 2017. The Company adopted this new standard in January 2018 and it did not have a material impact on its consolidated financial statements. In October 2016, the FASB issued ASU. 2016-16, Income Taxes (Topic 740): Intra-Entity Transfers of Assets Other than Inventory. This update requires entities to recognize the income tax consequences of an intra-entity transfer of an asset other than inventory when the transfer occurs. This update is effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. Early adoption is permitted as of the beginning of a fiscal year. The new standard must be adopted using a modified retrospective transition method, which is a cumulative-effective adjustment to retained earnings as of the beginning of the first effective reporting period. The Company adopted this new standard in January 2018 and it did not have a material impact on its consolidated financial statements. In May 2017, the FASB issued ASU 2017-09, Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting, which provides guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. This update is effective for annual reporting periods beginning after December 15, 2017. Early adoption is permitted. The Company adopted this ASU in January 2018 and it did not have a material impact on its consolidated financial statements.

Inventory

Inventory	12 Months Ended
	Dec. 31, 2018
Inventory Disclosure [Abstract]
Inventory	(3) Inventory The Company maintains a serial number tracking system that measures shelf life such that no lens that has aged beyond four years shall be delivered to a customer. During the years ended December 31, 2018 and 2017, inventory write-downs reflecting excess quantities on hand were recognized in the amount of $45,000 and $90,000, respectively, based on the age of the lens inventory, inserters, accessories and the refractive mix of the inventory. Finished goods inventory consists of the following (in thousands): December 31, 2018 2017 Lenses $ 22 $ 55 Accessories 37 72 Inventory $ 59 $ 127

Property and Equipment, net

Property and Equipment, net	12 Months Ended
	Dec. 31, 2018
Property Plant And Equipment [Abstract]
Property and Equipment, net	(4) Property and Equipment, net Property and equipment, net consist of the following (in thousands): December 31, 2018 2017 Office equipment and computers $ 52 $ 79 Leasehold improvements 189 214 Production equipment and facilities 760 802 Software 42 62 Furniture and vehicles 99 237 1,142 1,394 Less: accumulated depreciation (775 ) (917 ) Property and equipment, net $ 367 $ 477 Depreciation and amortization expense related to property and equipment for the years ended December 31, 2018 and 2017 was $109,000 and $322,000, respectively and classified as part of operating expenses in the Consolidated Statements of Operations and Comprehensive Loss for all periods. In connection with the closure of an office facility in December 2017, approximately $67,000 of unrecognized depreciation for furniture and leasehold improvements and $52,000 of engineering tools, molds and fixtures were recorded in the Consolidated Statements of Operations and Comprehensive Loss for the period ended December 31, 2017 (see Note 15).

Note Payable

Note Payable	12 Months Ended
	Dec. 31, 2018
Debt Disclosure [Abstract]
Note Payable	(5) Note Payable Note payable is summarized as follows (in thousands): December 31, 2018 2017 Noninterest bearing note payable to Neoptics A.G. $ — $ 518 Less present value discount — (38 ) Note payable, net — 480 Less current portion — 480 Note payable, long term $ — $ — Presbia Ireland, Limited (“Limited”), an indirectly-owned subsidiary of the Company, entered into an asset purchase agreement with Neoptics AG pursuant to which Limited acquired certain assets from Neoptics for an aggregate purchase price of 1.5 million Swiss Francs (approximately $1.5 million based on the exchange rate between the Swiss Franc and US Dollar on August 2, 2016), bearing no interest and payable in three equal installments on each of August 2, 2016, December 31, 2017 and December 31, 2018. Limited recorded the intangible asset and a loan discount using a rate of 9%. The remaining liability of $480,000 was recorded in the Company’s consolidated balance sheet, net of unamortized discount of $38,000 at December 31, 2017. Limited made a final payment of $0.5 million in cash in exchange for these patents and patent applications in the year ended December 31, 2018.

Secured Debt with Related Party

Secured Debt with Related Party	12 Months Ended
	Dec. 31, 2018
Class Of Stock Disclosures [Abstract]
Secured Debt with Related Party	(6) Secured Debt with Related Party On December 10, 2018, the Company and its wholly-owned subsidiary, Presbia USA, Inc., entered into and closed a Securities Purchase & Exchange Agreement with Richard Ressler, a member of the Company’s board of directors and its majority stockholder. Under the terms of the agreement, Mr. Ressler, in a private placement transaction, provided Presbia USA with a secured loan in the aggregate principal amount of $3.5 million less legal and professional fees of $0.2 million, resulting in net proceeds of approximately $3.3 million. As part of this transaction, Mr. Ressler redeemed (i) 100 preferred shares of Presbia PLC, (ii) 4,900 preferred shares of Presbia USA, Inc and (iii) 339 dividends preferred shares dividends of Presbia USA, Inc. for an amount equal to the original proceeds of $5.0 million plus accrued dividends of $0.3 million. This redemption came out of the proceeds of the 100 newly-designated Presbia PLC series 2 redeemable preferred shares and 5,239 newly-designated Presbia USA new preferred stock. Mr. Ressler also received a warrant to purchase ordinary shares. The number of ordinary shares covered by the warrant was determined based on the aggregate dollar amount of the securities involved in the financing transaction of $8.8 million, divided by the warrant exercise price of $0.60, for a total of 14,731,667 ordinary shares. The Secured Promissory Note has a five (5) year maturity, and Mr. Ressler has the right to call in the loan after a two (2) year period. Cash interest is paid annually in arrears at an annual rate of 10%, compounded monthly. An unamortized debt discount was established in the aggregate amount of approximately $1.6 million, which included direct costs of $0.2 million comprising of legal and professional fees, and $1.4 million in costs associated with the warrant issued in conjunction with the Secured Promissory Note. The 14,731,667 ordinary shares covered by the warrant issued in this transaction had an issue date fair value of $3.5 million, derived from a Black-Scholes calculation designed for use with warrants. The following assumptions, in addition to the exercise price of the warrant of $0.60, were used: (i) the period between the Initial Exercise Date and the Termination Date of the warrant of five (5) years (ii) due to its limited stock price volatility history, the Company used a peer group average of 73.95%, as permitted under ASC Topic 718 consistent with the term of the warrant at the time of the grant, (iii) a risk-free interest rate of 2.70%, based on the U.S. Treasury securities yield consistent with the expected term of the warrant at the time of the grant, (iv) the number of ordinary shares covered by the warrant, and (v) the number of common shares of the Company outstanding currently. The Company recognized $2.1 million as an adjustment to additional paid in capital, and $1.4 million as a debt discount, representing the fair value of 5,833,333 ordinary shares issued as an incentive to the secured loan principal of $3.5 million. These warrants were recorded as an offset to the note as unamortized transaction costs in the balance sheets at fair value, together with the aforementioned direct costs, which will be accreted to the loan amount over a five (5) year period using the effective interest method. The amount of $3,520,000 includes accrued interest of approximately $20,000 for the period of December 10, 2018 to December 31, 2018. Secured debt with related party consisted of the following as of the dates set forth below (in thousands): December 31, 2018 2017 Secured debt with related party $ 3,520 $ — Less current portion (20 ) — Secured debt with related party, long term 3,500 — Less unamortized transaction costs (1,585 ) — Secured debt with related party, net $ 1,915 $ —

Other Current Liabilities

Other Current Liabilities	12 Months Ended
	Dec. 31, 2018
Other Liabilities Current [Abstract]
Other Current Liabilities	(7) Other Current Liabilities Other current liabilities consist of the following as of the dates set forth below (in thousands): December 31, 2018 2017 Accrued payroll and severance related $ 89 352 Accrued professional fees 108 109 Accrued clinical expense 49 125 Accrued deferred rent expense — 236 Accrued other expense 53 46 Income tax payable 2 283 $ 301 $ 1,151

Shareholders' Equity

Shareholders' Equity	12 Months Ended
	Dec. 31, 2018
Equity [Abstract]
Shareholders' Equity	(8) Shareholders’ Equity Ordinary Shares As of December 31, 2018, our authorized share capital includes $400,000 and €40,000 divided into 350,000,000 ordinary shares of $0.001 each, (which we refer to as the ordinary shares), 50,000,000 preferred shares of $0.001 each and 40,000 deferred ordinary shares of €1.00 each. In the year ended December 31, 2018, the Company issued to Mr. Ressler warrants on a fully vested basis and priced at-the-money. The Company utilized the Black-Scholes valuation model, modified for use with warrants, for determining their fair value. The following assumptions, in addition to the exercise price of the warrant, were used: (i) the period between the Initial Exercise Date and the Termination Date of the warrant (ii) due to its limited stock price volatility history, the Company used a peer group average as permitted under ASC Topic 718 consistent with the term of the warrant at the time of the grant, (iii) a risk-free interest rate based on the U.S. Treasury securities yield consistent with the expected term of the warrant at the time of the grant, (iv) the number of ordinary shares covered by the warrant, and (v) the number of common shares of the Company outstanding currently. On April 12, 2018, Mr. Ressler received a warrant covering 1,953,125 ordinary shares of Presbia PLC at an exercise price of $2.56 per share. The aggregate fair value of the warrant was $3,126,000. In December 2018, the Company updated the Black-Scholes calculation of the April warrant using the aforementioned version of Black-Sholes designed for use with warrants. Due to warrants being highly dilutive, the revised Black-Scholes model takes into consideration the number of common shares currently outstanding and revises downward the fair value of the fair value of the option. As a result, the Company recorded an adjustment of $288,000 within APIC that revises the value associated with the warrants to $2,837,000 and increases the value associated with the preferred shares to $2,053,000, net of direct costs. On December 10, 2018, Mr. Ressler received a warrant covering 14,731,667 ordinary shares of Presbia PLC at an exercise price of $0.60 per share. The aggregate fair value of the warrant was $3,523,000. Given that the warrant issued in the December 10, 2018 transaction was an incentive to the Secured Loan with Mr. Ressler, the Company allocated $1,395,000, corresponding to the fair value of warrants of $3.5 million at an exercise price of $0.60, to unamortized transaction costs (see Note 6). The rights and preferences of the ordinary shares are as follows: (i) subject to the right of the Company to set record dates for the purposes of determining the identity of shareholders entitled to notice of and/or to vote at a general meeting, the right to attend and speak at any general meeting of the Company and to exercise one vote per ordinary share held at any general meeting of the Company; (ii) the right to participate pro rata in all dividends declared by the Company; and (iii) the right, in the event of the Company’s winding up, to participate pro rata in the total assets of the Company. The rights attaching to the ordinary shares may be subject to the terms of issue of any series or class of preferred shares allotted by the Company’s board of directors from time to time in accordance with our articles of association. Deferred Ordinary Shares Capital related to Presbia PLC at December 31, 2014 consisted of ordinary shares of €1.00 each (“Euro Ordinary Shares”) of $54,000, €1.00 par value, 40,000 authorized and issued with effective date of formation of February 6, 2014 (paid-in on January 10, 2014 with $1.35: €1.00), being $54,000 in aggregate. On January 14, 2015 the Company amended its memorandum and articles of association, resulting in the re-designation of the 40,000 Euro Ordinary Shares as deferred ordinary shares (“Deferred Ordinary Shares”). In August 2015, the Company cancelled 6 Deferred Ordinary Shares pursuant to the distribution of assets held by Presbia Holdings to its ordinary shareholders and 39,994 Deferred Ordinary Shares held by Presbia Holdings were transferred to Richard Ressler, one of the Company’s directors and its controlling shareholder,. Our articles of association provide that the holders of Deferred Ordinary Shares shall not be entitled to receive notice of, nor attend, speak or vote at, any general meeting of the Company and the holders of Deferred Ordinary Shares shall not be entitled to receive any dividend or distribution declared, made or paid or any return of capital or to any further or other right of participation in the assets of the Company. On a winding up of, or other return of capital (other than on a redemption of any class of shares in the capital of the Company) by the Company, the holders of Deferred Ordinary Shares are entitled to participate in such return of capital or winding up, such entitlement to be limited to the repayment of the amount paid up or credited as paid up on such Deferred Ordinary Shares, which shall be paid only after the holders of ordinary shares have received payment in respect of such amount as is paid up or credited as paid up on those ordinary shares held by them at that time, plus the payment in cash of $5,000,000 on each such ordinary share. The rights attaching to the Deferred Ordinary Shares may be subject to the terms of issue of any series or class of preferred shares allotted by the Company’s board of directors from time to time in accordance with our articles of association. Preferred Shares Our authorized share capital also includes 50,000,000 Series 2 Redeemable Preferred Shares of $0.001 each and 8,000 USA New Preferred Shares of $0.01 each, which we refer to as preferred shares. As of December 31, 2018, 100 Series 2 Redeemable Preferred Shares and 5,239 USA New Preferred Shares have been issued and are outstanding. USA New Preferred Shares accrue dividends at the rate of 15% per annum, and as of December 31, 2018, the Company recognized $45,000 as USA new preferred shares dividends in the Consolidated Statement of Operations and Comprehensive Loss and increased the same amount to the carrying value of the preferred shares. On April 12, 2018, as part of a Stock Purchase Agreement between the Company and Mr. Ressler, the Company issued to Mr. Ressler (i) 100 preferred shares of Presbia PLC, (ii) 4,900 preferred shares of Presbia USA, Inc and (iii) a warrant to purchase 1,953,125 ordinary shares of Presbia PLC at an exercise price of $2.56 per share for an aggregate price of $5.0 million, less legal and professional fees of $0.1 million, resulting in net proceeds of approximately $4.9 million. In a financing transaction that closed on December 10, 2018, Mr. Ressler exchanged all 4,900 preferred shares of Presbia USA, Inc. stock and 339 in preferred shares dividends for 5,239 newly-designated Presbia USA New Preferred Stock. Mr. Ressler also purchased 100 of Presbia PLC’s newly-designated series 2 redeemable preferred shares for an aggregate purchase price of $100,000, with proceeds for the purchase of such series 2 redeemable preferred shares being applied (by way of set-off) to redeem and retire all 100 of the preferred shares of Presbia PLC previously purchased by him in April 2018. The aggregate fair value of the preferred shares issued in April was $1,765,000, and as aforementioned, the Company recorded an adjustment of $288,000 within APIC that revised the value associated with the warrants to $2,837,000 and increased the value associated with the preferred shares to $2,053,000, net of direct costs. In a financing transaction that closed on December 10, 2018, we redeemed from Mr. Ressler (i) 100 preferred shares of Presbia PLC, (ii) 4,900 preferred shares of Presbia USA, Inc. and (iii) 339 preferred shares dividends of Presbia USA, Inc. for an amount equal to the original proceeds. This redemption came out of the proceeds of the 100 newly-designated Presbia PLC series 2 redeemable preferred shares and 5,239 newly-designated shares of Presbia USA new preferred stock. Shares of USA New Preferred Shares are redeemable by the Company out of funds lawfully available at a price equal to the original issue price per share, plus all accruing dividends and any declared by unpaid dividends thereon, upon the occurrence of a Liquidation Event. Prior to the occurrence of a Liquidation Event, the Company has the unconditional unilateral right to redeem any USA New Preferred Share at any time for the Redemption Price upon approval of a majority of the members of the Company’s board of directors that are independent of the holders or the USA New Preferred Shares being redeemed. To the extent permitted by applicable law, Richard Ressler has the option to convert all or part of the accrued value of the USA New Preferred Shares into a secured loan to Presbia USA on terms substantially similar to the Presbia USA Loan issued on December 10, 2018. The accrued value of such USA New Preferred Shares shall be equal to the sum of the Original Issue Price paid for such shares and the accrued but unpaid dividend on such shares that would be payable if a Liquidation Event had occurred and the proceeds distributed to Richard Ressler as of the date of the conversion. Our articles of association authorize our Board, without shareholder approval, to determine the terms of the preferred shares that may be issued by us. Our Board is authorized, without obtaining any shareholder vote or consent, unless expressly provided by the terms of that class or series of class of shares, to provide from time to time for the issuance of ordinary shares or other classes or series of shares and to establish the characteristics of each such other class or series, including the number of shares, designations, relative voting rights, dividend rights, liquidation and other rights, redemption, repurchase or exchange rights and any other preferences and relative, participating, optional or other rights and limitations not inconsistent with applicable law. Shares Issuable Pursuant to Services Agreement with OCV Management, LLC On December 14, 2017, the Company concluded a services agreement with OCV Management, LLC, a related party co-founded by Richard Ressler and Mark Yung, the Company’s Chairman and CEO, for the purpose of providing management services for the Company for the period commencing December 14, 2017 until terminated upon thirty (30) days’ prior written notice by either of the parties. OCV Management, LLC will receive an annual fee of $250,000, payable annually in arrears. The obligation will be settled in the form of ordinary shares issued by the Company in a private offering on January 2 of each year for services provided in the preceding year. For 2018, 72,464 shares were issued on January 2, 2019, determined by dividing $250,000 by the closing price of the Company’s ordinary shares of $3.45 as of January 2, 2018.

Equity Based Awards

Equity Based Awards	12 Months Ended
	Dec. 31, 2018
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Equity Based Awards	(9) Equity Based Awards Presbia Incentive Plan On January 14, 2015, the Company approved a compensation incentive plan (the “Presbia Incentive Plan”). The Presbia Incentive Plan permits the Company to grant awards of options, restricted shares, share appreciation rights, restricted stock units, performance shares, performance share units, dividend equivalent rights in respect of awards and other share-based and cash-based awards, including annual and long-term cash incentive awards. A total of 2,500,000 ordinary shares were authorized for issuance under the Presbia Incentive Plan of which approximately 186,314 were available on December 31, 2018 for future grants and awards. The exercise price of each option award shall be determined by the Board of Directors (or a committee thereof) at the date of grant in accordance with the terms of the Presbia Incentive Plan awards, and generally vest 20% annually over a five-year period and expire no later than 10 years from the grant date. The Presbia Incentive Plan terminates on January 14, 2025, unless terminated earlier by the board of directors. Awards under the Presbia Incentive Plan may be granted to employees, directors, consultants and other persons who perform services for the Company or a subsidiary of the Company. The following table shows share-based compensation expense based upon all equity awards issued by Presbia PLC included in the Consolidated Statements of Operations and Comprehensive Loss for the years ended December 31, 2018 and 2017. The Company recorded a credit of $547,000 and $970,000 as a result of the reversal of stock-based compensation for participants whose relationship with the Company terminated in the years ended December 31, 2018 and 2017, respectively. Pursuant to the Services Agreement with OCV Management, LLC (See note 8) approximately $250,000 and $12,000 was recorded as stock-based compensation expense as part of general and administrative in the following table for the fiscal years ended December 31, 2018 and 2017, respectively. Year Ended December 31, 2018 2017 Research and development $ (136 ) $ 251 General and administrative 547 951 Sales and marketing 119 (34 ) $ 530 $ 1,168 Options The following table sets forth the Company’s option activity for the year ended December 31, 2018: Number of Presbia PLC Shares Weighted Average Exercise Price Per Share Aggregate Intrinsic Value Balance, January 1, 2018 849,100 $ 9.77 — Granted 939,172 $ 1.73 — Exercised — $ — — Forfeited/cancelled/expired (174,600 ) $ 8.38 — Balance, December 31, 2018 1,613,672 $ 5.24 — Vested, December 31, 2018 656,000 $ 9.84 — Non Vested, December 31, 2018 957,672 $ 2.10 — Exercisable, December 31, 2018 653,000 $ 9.84 — Employee Options The Company utilizes the Black-Scholes valuation model for estimating the fair value of granted stock options with the following assumptions in addition to the closing price of the Company’s ordinary shares on the date of the grant: (i) the Company estimates the expected term of the option utilizing the simplified method because of its limited history of option exercise activity and its options meet the criteria of a "plain-vanilla" option as defined by the Securities Exchange Commission (ii) due to its limited stock price volatility history, the Company uses a peer group average as permitted under ASC Topic 718 consistent with the expected term of the stock option at the time of the grant and (iii) applies a risk-free interest rate based on the U.S. Treasury securities yield consistent with the expected term of the option at the time of the grant. The simplified method calculates the expected term as the average of the weighted average vesting period and contractual terms of the award. For those options granted to employees, stock-based compensation expense was based upon the fair value of the option as of the grant-date and attributed to future reporting periods on a straight-line basis over the vesting period, or the requisite service period. The Company adopted ASU 2016-09 on January 1, 2018, electing to account for forfeitures when they occur. The Company issued 939,172 and 0 employee options during the years ended December 31, 2018 and 2017, respectively. Options granted to employees in 2018 vest 20% annually over a five-year period and expire 6.75 years from the grant date. Options granted to directors in in 2018 have a one-year vesting period and expire 6.75 years from the grant date. The Company did not issue employee options during the year ended December 31, 2017. Non-Employee Options During the years ended December 31, 2018 and 2017, the Company did not grant options to non-employee consultants and medical advisors. Grants issued prior to 2017 were fully vested as of December 31, 2018. In contrast to the determination of the fair value of options granted to employees, which are determined based upon the grant-date assumptions and applying the Black-Scholes model, the fair values for non-employee options and the related stock-based compensation expense are remeasured each financial reporting period based upon the assumptions applicable on the dates in which the financial statements are prepared, which are disclosed in the following table: Year Ended December 31, 2018 2017 Stock price per share $0.85 -$1.95 $1.31 -$2.83 Expected term 6.6 - 7.4 Yrs. 7.7 - 8.3 Yrs. Volatility 72.9% - 77.3% 69.3% - 85.8% Dividends — — Risk-free rate 2.6% - 2.8% 2.2% - 2.4% Restricted Shares The following table sets forth the Company’s restricted share activity for the year ended December 31, 2018: Unvested Number of Shares Weighted Average Fair Value per Share Balance, December 31, 2017 134,367 $ 3.78 Granted 35,303 $ 2.27 Vested (127,228 ) $ 3.23 Forfeited/cancelled — $ — Unvested, December 31, 2018 42,442 $ 5.47 During the years ended December 31, 2018 and 2017, 35,303 and 89,166 restricted shares were awarded, respectively. Restricted Stock Units During the year ended December 31, 2018, the Board of Directors approved the awards of an aggregate of 170,000 restricted stock units (“RSU” or “RSU’s” or “RSU Plan”), respectively, to an officer and an employee in accordance with the guidelines provided by the Presbia Incentive Plan. One of these awards include a performance provision as well as a provision that the recipient must be employed as a condition of vesting. The following table sets forth the Company’s RSU activity for the year ended December 31, 2018: Unvested Number of Shares Weighted Average Fair Value per Share Balance, December 31, 2017 739,000 $ 2.09 Granted 170,000 $ 2.00 Vested — $ — Forfeited/cancelled (409,000 ) $ 2.95 Unvested, December 31, 2018 500,000 $ 1.36 Unrecognized Share-based Compensation As of December 31, 2018 and 2017, there were $0.9 million and $0.5 million, respectively, of unrecognized compensation expense related to employee and non-employee options of the Company, which collectively is expected to be recognized by the Company over the weighted average vesting period of 1.9 and 1.5 years, respectively. Unrecognized compensation expense for the same periods related to restricted shares was $0.2 million and $0.2 million, respectively, and is expected to be recognized over the weighted average vesting periods of 1.6 and 1.6 years, respectively. As of December 31, 2018 and 2017, there were approximately $0.4 million and $7.3 million of unrecognized compensation expense with respect to the RSU’s over a weighted average remaining derived service period of 1.9 and 2.0 years, respectively.

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2018
Related Party Transactions [Abstract]
Related Party Transactions	(10) Related Party Transactions The following table sets forth the amounts due to related parties reflected in the accompanying consolidated balance sheets (in thousands): Year Ended December 31, 2018 2017 Payable to related parties-current: Management services provided by related parties $ 39 $ 35 Less current portion 39 23 Management services provided by related parties, long-term $ — $ 12 Since 2011, Orchard Capital Corporation (“Orchard”), which is wholly-owned by Mr. Ressler, has provided financial analysis and bookkeeping, accounting, legal, compliance and directorial services to the Company pursuant to a Services Agreement. During the years ended December 31, 2018, and 2017, the Company recognized general and administrative expense of $5,000 and $14,000, respectively, for services invoiced by Orchard. As of December 31, 2018 and 2017, amounts due to Orchard for management and accounting services amounted to $1,000 and $3,000, respectively. Commencing with the second quarter of 2013, the Company has received human resources management services, payroll services, IT support and risk management services from CIM Group, an entity in which Mr. Ressler has a controlling interest. The Company has incurred charges of $38,000 and $37,000 payable to CIM Group for such services for the years ended December 31, 2018 and 2017, respectively. As of December 31, 2018 and 2017, amounts due to CIM Group for human resources, payroll, information technology and legal services amounted to $26,000 and $19,000, respectively. On December 14, 2017, the Company concluded a services agreement with OCV Management, LLC, a related party co-founded by Mr. Ressler and Mark Yung (see Note 8), for the purpose of providing management services for the Company for the period commencing December 14, 2017 until terminated upon thirty (30) days’ prior written notice by either of the parties. OCV Management, LLC will receive an annual fee of $250,000, payable annually in arrears. The obligation will be settled in the form of ordinary shares issued by the Company in a private offering. For 2018, the number of shares to be issued was determined by dividing $250,000 by the closing price on January 2, 2018 and 72,464 shares were issued on January 2, 2019. The program continues into 2019. On April 12, 2018, the Company and its wholly-owned subsidiary, Presbia USA, Inc. and Mr. Ressler entered into a Stock Purchase Agreement pursuant to which Mr. Ressler acquired 100 preferred shares of Presbia PLC stock and 4,900 preferred shares of Presbia USA, Inc. stock for an aggregate price of $5.0 million, and a warrant to purchase 1,953,125 ordinary shares of Presbia PLC at an exercise price of $2.56 per share. The warrant is exercisable for five years and contains cashless exercise provisions. In a finance transaction that closed on December 10, 2018, the Company and its wholly-owned subsidiary, Presbia USA, Inc., entered into and closed a Securities Purchase and Exchange Agreement with Mr. Ressler. Under the terms of the agreement, Mr. Ressler provided a secured loan in the aggregate principal amount of $3.5 million. He also exchanged all 4,900 preferred shares of Presbia USA, Inc. stock for 5,239 newly-designated Presbia USA New Preferred Stock and he was issued a warrant to purchase 14,731,667 ordinary shares at an exercise price of $0.60 per share, subject to adjustments as provided under the terms of the warrant. In addition, he purchased 100 of Presbia PLC’s newly-designated series 2 redeemable preferred shares for an aggregate purchase price of $100,000, with such proceeds for the purchase of such series 2 redeemable preferred shares being applied (by way of set-off) to redeem from Mr. Ressler and retire all 100 of the preferred shares of Presbia PLC previously purchased by him in April 2018. Pursuant to ASC 805-50-25, “Transactions Between Entities Under Common Control” and other SEC guidance, due to the lack of economic substance, this transaction between entities under common control was accounted for as a an adjustment to Additional Paid-In Capital and no gain or loss was recorded in the Company’s Consolidated Statements of Operations and Comprehensive Loss.

Operating Segments and Geograph

Operating Segments and Geographic Information	12 Months Ended
	Dec. 31, 2018
Segment Reporting [Abstract]
Operating Segments and Geographic Information	(11) Operating Segments and Geographic Information The Company operates in one operating segment, the restoration of clear vision caused by presbyopia. The Company provides the refractive lens for patient surgeries and accessories for procedures performed exclusively outside the United States. Revenue originating in the United States is limited to intercompany transactions that do not result in any revenue generating activities to any individual or physician in the United States, and these amounts are eliminated upon consolidation. The operating losses in the United States result primarily from research and development and general and administrative costs while the operating losses in the foreign operations result primarily from sales and marketing costs and an allocation of general and administrative costs to foreign operations. Revenues from external customers to individual countries are allocated based on the location of the customer. For the periods presented, there was no more than four customers in each individual country. The following table sets forth the Company’s revenues generated from external customers located in foreign countries and long-lived assets by area (in thousands): Year Ended December 31, Revenues 2018 2017 Canada $ — $ 1 Ireland — 14 Italy 1 — The Netherlands — (1 ) Germany 20 — Total $ 21 $ 14 Year Ended December 31, Long-lived Assets 2018 2017 U.S. 346 453 Foreign 21 24 Total $ 367 $ 477 In the years ended December 31, 2018 and 2017 there were five and four customers, respectively, that represented 100% of total sales recognized for each year. As of December 31, 2018, the Company was not authorized to manufacture or sell any of its products or services within the United States and, as a result, all of the Company’s revenues are derived from foreign customers. With respect to suppliers for the microlens, the Company has a five-year supplier agreement that expired in January 2017 with a lens manufacturer in Israel from which the Company received 100% of its lens supply for use in commercial activities outside the United States. The Company also has its own manufacturing facility in Irvine, California that we believe can be scaled to meet excessive lens demand or a disruption of supply sourced from outside the United States.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2018
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	(12) Commitments and Contingencies Facility Leases In May 2012, the Company entered into a five-year non-cancelable lease for office and manufacturing space in Irvine, California that was renewed on June 1, 2016 and provided for an extension of five consecutive years starting from the original lease expiration date of May 31, 2017 through May 31, 2022. The Company maintains a one-year lease (which is now month to month) in Dublin, Ireland that commenced on December 1, 2013. In February 2018, it terminated a 30-month lease in Amsterdam, the Netherlands, that commenced on January 1, 2016. This termination was based on a mutual agreement with the landlord. In December 2017, the Company vacated one of its Irvine, California locations and consolidated its operations into another location in Irvine. At December 31, 2017, a liability of $222,000, representing the fair value of the remaining lease obligation over the remaining 33 months was recorded as part of the short-term portion of deferred rent in the Consolidated Balance Sheet. During the year ended December 31, 2018, the Company sublet the facility and settled the remaining lease obligation with the landlord, releasing the Company from any future obligations under the lease. Aggregate rent expense for the years ended December 31, 2018 and 2017 was $384,000 and $867,000, respectively. The following table shows the annual base rental cost over the term of the leases (in thousands). Years Ended December 31, Obligations Under Facility Leases 2019 $ 292 2020 298 2021 287 2022 119 Total $ 996 Contingencies From time to time, the Company may be subject to legal proceedings and claims arising in the ordinary course of business. Management does not believe that the outcome of any of these matters will have a material effect on the Company’s consolidated financial statements.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Income Taxes	(13) Income Taxes The provision for income taxes consists of the following (in thousands): Year Ended December 31, 2018 2017 Current provision: Federal $ — $ — State 2 2 Foreign (237 ) 243 Total current $ (235 ) $ 245 Deferred provision Federal (1,103 ) (3,335 ) State — — Foreign (59 ) (1,065 ) Total deferred (1,162 ) (2,270 ) Valuation allowance 1,162 2,270 Total deferred — — Total income tax (benefit) provision $ (235 ) $ 245 A reconciliation of the federal statutory rate to the effective rate is as follows: Year Ended December 31, 2018 2017 Expected income tax benefit at federal statutory rate 21.0 % 35.0 % State tax provision, net of federal benefit (0.0 %) (0.0 %) Foreign rate differential (8.1 %) (15.0 %) Nondeductible expenses (0.0 %) (0.1 %) Foreign Tax 2.8 % (1.4 %) Change in valuation allowance (13.5 %) (4.2 %) Effect of Change in Tax Rate 0.0 % (9.3 %) Other 0.6 % (6.5 %) Income tax provision (benefit) 2.7 % (1.4 %) The components of the Company’s deferred tax assets are summarized as follows (in thousands): Year Ended December 31, 2018 2017 Deferred tax assets: Net operating loss carryforwards $ 6,279 $ 5,019 Accrued expenses 47 31 Stock based compensation 0 0 Deferred tax assets 6,326 5,050 Valuation allowance (6,310 ) (5,033 ) Net deferred tax assets 16 17 Deferred tax liabilities: Depreciation (16 ) (17 ) Total deferred tax liabilities (16 ) (17 ) Net deferred tax asset $ — $ — The valuation allowance has been established to offset the Company’s net deferred tax assets, as realization of such assets is not considered to be more likely than not due to the Company’s history of losses and uncertainties regarding the Company’s ability to generate future taxable income sufficient to realize the benefit of these deferred tax assets. The Company has U.S. Federal net operating loss (“NOL”) carryforwards of approximately $16.3 million and $11.1 million for December 31, 2018 and 2017 respectively, subject to potential limitations pursuant to Internal Revenue Code section 382 as discussed below. The federal NOL carryforwards will begin to expire in 2033, unless previously utilized. The Company has NOL carryforwards in Ireland of $21.8 million and $21.5 million for December 31, 2018 and 2017, respectively. Under Irish rules, only such losses that occur within a three year period prior to commencing trading can be utilized to offset future trading taxable income. The Company has NOL carryforwards in Germany of $0.8 million that can be carried forward indefinitely. At December 31, 2018, the Company has state NOL carryforwards of approximately $0.6 million, which will begin to expire in 2028, unless previously utilized. Pursuant to Sections 382 of the Internal Revenue Code (the “Code”), annual use of the Company’s NOL carryforwards may be limited in the event a cumulative change in ownership of 50% of certain shareholders occurs within a three year period. An ownership change may limit the amount of NOL carryforwards that can be utilized annually to offset future taxable income and tax. In general, an “ownership change” as defined by Section 382 of the Code results from a transaction or series of transactions over a three-year period resulting in an ownership change of more than 50 percentage points of the outstanding stock of a company by certain shareholders. On December 22, 2017, the President signed the Tax Cuts and Jobs Act (the 2017 Act) into law. The Act has financial reporting implications for all companies with US operations, including reduction of the U.S. federal corporate tax rate from 35 percent to 21 percent. We remeasured the deferred taxes as of December 31, 2018 at the new corporation rate of 21% . Due to full valuation allowance, the change in deferred taxes was fully offset by the change in valuation allowance. The 2017 Act has no significant impact on the 2017 and 2018 financial statements. On December 22, 2017, Staff Accounting Bulletin No. 118, or SAB 118, was issued to address the application of GAAP in situations when a registrant does not have the necessary information available, prepared, or analyzed (including computations) in reasonable detail to complete the accounting for certain income tax effects of the 2017 Act. We previously provided a provisional estimate of the effect of the Tax Act in our financial statements. In the fourth quarter of 2017, we completed our analysis to determine the effect of the Tax Act and recorded immaterial adjustments as of December 31, 2017. As of December 31, 2018, the Company has no unrecognized contingent liabilities. The Company does not anticipate a significant increase in the unrecognized tax benefits over the next 12 months. The Company’s policy is to recognize interest expense and penalties related to income tax matters as a component of the income tax provision. As of December 31, 2018 and December 31, 2017, the Company did not have any material tax related accrued interest and penalties on its balance sheet or on its statement of operations. Due to net operating loss carryovers, the U.S. federal and state returns are open to examination by the Internal Revenue Service and state jurisdictions for years 2015 through 2018. The foreign income tax returns are open to examination for the years 2014 through 2018.

Fourth Quarter 2017 Adjustments

Fourth Quarter 2017 Adjustments	12 Months Ended
	Dec. 31, 2018
Restructuring And Related Activities [Abstract]
Fourth Quarter 2017 Adjustments	(14) Fourth Quarter 2017 Adjustments In December 2017, the Company announced a reorganization which resulted in a reduction of 15 employees, or 38.5% of total headcount, which affected payroll, benefits, severance and incentive pay expenses; reduced need for office space which resulted in vacant office space and termination costs; and adjustments to stock-based compensation expense related to modification of equity awards for terminated employees. In addition, the Company is recognizing a tax reserve of $238,000 for unpaid withholding taxes due to Irish tax authorities. The total amount of fourth quarter adjustments was a reduction in operating expense of $1,078,000 and an increase of tax provision expense of $238,000. • Compensation Related - ($465,000) In December 2017, 15 employees were terminated as the Company reprioritized its efforts towards its FDA clinical trial. Post-employment costs were approximately $332,000 consisting of severance costs to be paid out primarily over a six-month period ending June 2018 and a reversal of $797,000 in accrued incentive compensation costs for amounts that were accrued in 2017 but were not payable as of December 31, 2017. • Facilities Related - $357,000 Also, in December 2017, the Company vacated one of its Irvine, California facilities and consolidated its operations into another facility also located in Irvine. As of December 31, 2017, the remaining lease term of the vacated facility, of approximately 8,500 square feet, was 33 months through September 30, 2020. The Company recorded a current liability of $222,000 representing the fair value of the remaining lease obligation as part of the short-term portion of deferred rent on the Consolidated Balance Sheet as of December 31, 2017 (see note 6). The determination of the fair value was inclusive of reasonable prospective sublease assumptions. In 2018, the Company sublet the facility and settled the remaining lease obligation. In addition, the Company recorded write-downs of leasehold expenses, furniture and fixtures of an aggregate of $89,000 and accrued expense of $8,000 for unneeded telecom facilities. The Company also wrote down to net realizable value certain engineering tools, molds and fixtures related to discontinued engineering programs in the amount $52,000. • Stock-Based Compensation Related – ($970,000) Equity awards granted by the Company do not include provisions to extend the terms and conditions related to vesting or exercising an award beyond the date of termination of the optionee (or holder), with the exception of stock option grants that contain a provision that allows the holder to exercise vested options (vesting must have occurred on or prior to termination date) for a period of 90 days following termination. On the date of reorganization, the Company extended the terms and conditions for all equity grants for all terminated employees providing at least a one-year extension past the termination date for all vested stock options (Type I modification as prescribed by ASC Topic 718), and, in certain cases, the acceleration of unvested options or restricted share awards (Type III modification as prescribed by ASC Topic 718). For those terminated employees with RSU grants based on a market condition, the Company granted a one-year extension to vest according to the same market conditions as defined in the original grants. Generally, when a modification of an award occurs, the prior periods’ expense recognition associated with all unvested awards is reversed in the period of the modification on the basis that the old award is being exchanged for a new award. This resulted in a reduction of stock-based compensation expense of $1,350,000. The Company then compared the relative fair values of the old award with the terms and conditions of the modified award immediately before and after the date of modification and recorded the increase in fair value as stock-based compensation expense in the amount of $380,000, also in the same period of the date of modifications, resulting in a net reduction of stock-based compensation expense of $970,000. • Irish Taxes - $238,000 Under Irish law non-executive Directors of Irish companies, regardless of the tax residency of such Directors, are subject to Irish income tax related to meetings held in Ireland. The Company is also jointly liable for the Irish taxes. As of December 31, 2017, the Company had not paid or arranged to be paid approximately $238,000 in withholding of income taxes required under Irish law including potential penalties and interest costs associated with the remuneration of certain board of director members with tax residencies outside of Ireland for the fiscal years 2015 to 2017. In December, 2017, the Company recognized a reserve of $238,000 under FIN 48 , Accounting for Uncertainty of Income Taxes.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2018
Subsequent Events [Abstract]
Subsequent Events	(15) Subsequent Events None.

Basis of Presentation and Des_2

Basis of Presentation and Description of the Business (Policies)	12 Months Ended
	Dec. 31, 2018
Accounting Policies [Abstract]
Going Concern Uncertainty	Going Concern Uncertainty At December 31, 2018, the Company has an accumulated deficit of $96.8 million and it expects to incur additional operating losses through 2019, and possibly further. As it continues to incur losses, the Company’s transition to profitability will depend on the successful development, approval and commercialization of its microlens. The Company may never achieve profitability, and unless and until it does, it will need to continue to raise additional capital. Based on the Company’s current business plan, management believes that its cash at December 31, 2018, will not be sufficient to meet its anticipated cash requirements during the twelve-month period subsequent to the issuance of the financial statements included in this Annual Report on Form 10-K. These factors raise substantial doubt about the Company’s ability to continue as a going concern within one year from the date this Annual Report on Form 10-K is filed with the U.S. Securities and Exchange Commission (SEC). The Company’s current commercialization strategy is targeted to countries where the Company can establish the market for its technology. This commercialization strategy will undergo continual prioritization and in the future the Company may adjust its commercialization efforts to preserve its existing cash or realize better results than anticipated which could have a positive impact on cash. The Company’s U.S. pivotal clinical trial and planned FDA approval is its highest priority. The Company must raise additional capital to fund its operations. It may raise additional capital through equity offerings, debt financings, collaborations and/or licensing arrangements. Additional funds may not be available when the Company needs them on terms that are acceptable to the Company, or at all. If adequate funds are not available on acceptable terms, the Company may be required to delay, reduce the scope of, or curtail, its operations. To the extent that the Company raises additional funds by issuing equity securities, its shareholders will experience dilution, and debt financing, if available, may involve restrictive covenants.
Use of Estimates	Use of Estimates The preparation of the Company’s consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires that management makes estimates and assumptions that are included in the consolidated financial statements and accompanying notes. The actual results may differ from those estimates.
Segment Information	Segment Information In accordance with Accounting Standard Codification (“ASC”) 280-10-50, Segment Reporting
Foreign Currency	Foreign Currency The functional currency of subsidiaries outside the United States of America is the U.S. Dollar. Transactions in foreign currencies during the year are re-measured at rates of exchange on the dates of the transactions. Gains and losses related to re-measurement of items arising through operating activities are accounted for in the statement of operations and comprehensive loss and included in general and administrative expense. Aggregate foreign exchange loss was $12,000 and $59,000 for the years ended December 31, 2018 and 2017, respectively.
Reclassifications	Reclassifications Certain prior year balances within the consolidated financial statements have been classified to conform to current year presentation.
Concentrations of Credit Risks	Concentrations of Credit Risk Cash is generally deposited in demand deposit accounts that, from time to time, may exceed insurable limits. The Company has not experienced any losses from its deposits of cash.
Fair Value of Financial Instruments	Fair Value of Financial Instruments The carrying values of certain of the Company’s financial instruments, such as prepaid expenses, accounts payable and accrued expenses, approximate fair value due to their short maturities. The Company’s debt obligation approximates fair value as a result of imputed interest which approximates prevailing market rates. Amounts payable to related parties, including the payable due to the Parent, which has no fixed maturity or expiration date, do not have readily determinable fair values.
Cash	Cash The Company considers highly liquid investments with original maturities less than 90 days to be cash equivalents. As of December 31, 2018 and 2017, the Company had no such short-term investment instruments and maintained its cash in bank demand deposit accounts.
Inventory	Inventory The Company accounts for inventory at the lower of cost and net realizable value. Inventory is stated at weighted average cost, which is determined by applying the current average cost to the ending inventory. Inventory consists of lenses and lens inserters and other accessories used by physicians in the surgical process associated with the lenses. The Company maintains serialized records of all lenses, including the five-year expiration date of each lens, after which the lens cannot be sold. The Company considers the expiration dates of lenses, in addition to comparing the carrying amount of inventory to expected demand, and will write-down inventory for amounts determined to be excess or obsolete.
Property and Equipment	Property and Equipment Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation of property and equipment is computed using the straight-line method over their estimated useful lives of three to ten years. Leasehold improvements are amortized over the lesser of the useful life of the asset or the remaining term of the lease. Repairs and maintenance of property and equipment are expensed as incurred. Upon retirement or sale, the original cost and accumulated depreciation are removed and any gain or loss is recognized in the consolidated statements of operations and comprehensive loss.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets The Company reviews the recoverability of long-lived and finite-lived intangible assets when circumstances indicate that the carrying amount of assets might not be recoverable. This evaluation is based on various analyses, including undiscounted cash flow projections. In the event undiscounted cash flow projections indicate impairment, the Company would record an impairment based on the fair value of the assets at the date of the impairment.
Intangible Assets	Intangible Assets On August 2, 2016, Presbia Ireland, Limited, a wholly-owned subsidiary of the Company, entered into an asset purchase agreement (the “Agreement”) with Neoptics AG (“Neoptics”) pursuant to which the Company acquired certain assets from Neoptics for an aggregate purchase price of 1.5 million Swiss Francs (approximately $1.5 million based on the exchange rate between the Swiss Franc and the U.S. Dollar on August 2, 2016) payable in three equal installments on each of August 2, 2016, December 31, 2017 and December 31, 2018. The assets acquired include patents, pending patents, and other immaterial assets. Effective August 2, 2016, the Company became responsible for all expenses associated with such assets. Pursuant to the terms of the Agreement, the acquisition closed on August 2, 2016. Substantially all of the fair value of the gross assets acquired is concentrated in the acquired intellectual property rights or patents and not in the trademarks, documents or electronic data obtained from the Seller. The Company determined the intellectual property right or patents were akin to inputs within the scope of ASC 805 “Business Combinations” and that no substantive processes were acquired in the assets acquisition. Therefore, the Company applied the asset acquisition accounting guidance in ASC 805-50-30 “ Initial Measurement of Acquisition of Assets Rather than a Business The Company made a final payment of $0.5 million in cash in exchange for these patents and patent applications in the year ended December 31, 2018. The useful life of the patents was determined to be 12 years and 4 months and will be amortized through November 25, 2028. The Company recorded amortization expense of approximately $136,000 with net carrying amount of approximately $1,344,000 as of December 31, 2018. For fiscal years 2019 to 2022, approximately $135,000 will be recorded annually as amortization expense for the Neoptics assets. The Company reviews its long-lived intangible assets for impairment at least annually or more frequently if impairment indicators arise. In evaluating the potential for impairment of the Neoptics assets, we make assumption regarding future operating performance, business trends and future useful life of these assets. As a result of these evaluations, the Company did not recognize impairment charges for the years ended December 31, 2018 and 2017, as it believes that the carrying value of these assets do not exceed their fair value. Costs incurred to develop software for the Company’s website are capitalized and amortized over the estimated useful life of the software and are included in intangible assets. Costs related to design or maintenance of website development is expensed as incurred. For the years ended December 31, 2018 and 2017, there were no capitalized costs associated with website development. Amortization expense of $1,000 and $15,000 was recorded the years ended December 31, 2018 and 2017, respectively.
Net Loss per Common Share	Net Loss per Common Share Basic net loss per ordinary share is calculated by dividing net loss, as adjusted for dividends on the USA New Preferred Shares in the period, by the weighted average number of ordinary shares outstanding during the reporting period, less unvested restricted stock awards. Diluted net loss allocated to ordinary shareholders per share is calculated based on the weighted average number of ordinary shares and dilutive potential ordinary shares outstanding during the period. Dilutive potential ordinary shares consist of the shares issuable upon the exercise of stock options and warrants, and upon the vesting of restricted shares under the treasury stock method. In net loss periods, basic and diluted net loss per share are identical since the effect of potential ordinary shares is anti-dilutive and therefore excluded. Basic and diluted net loss per share were calculated as follows (in thousands, except share and per share data): December 31, 2018 2017 Net Loss $ (8,415 ) $ (16,998 ) USA new preferred shares dividends $ 45 $ - Net loss attributable to common shareholders $ (8,460 ) $ (16,998 ) Weighted average shares outstanding – basic and diluted 17,077,817 16,298,505 Basic and diluted net loss per share $ (0.50 ) $ (1.04 ) The following potentially dilutive securities were excluded from the computation of diluted weighted average shares outstanding because their inclusion would have been antidilutive: December 31, 2018 2017 Options to purchase common stock 1,129,324 1,037,964 Restricted shares 49,189 — Warrant to purchase common stock (1)(2) 16,684,792 — Series 2 Redeemable Preferred Shares and USA New Preferred Shares outstanding 5,339 — Total potentially dilutive securities excluded from denominator of the diluted earnings per share Computation 17,868,719 1,037,964 (1) Includes 1,953,125 warrants to purchase ordinary shares of Presbia PLC at a price of US$2.56 per ordinary share, granted April 12, 2018 (see Note 8). (2) Includes 14,731,667 warrants to purchase ordinary shares of Presbia PLC at a price of US$0.60 per ordinary share, granted December 10, 2018 (see Note 8).
Revenue Recognition	Revenue Recognition Prior to 2018, we recognized revenue when there was persuasive evidence that an arrangement existed with our customers, selling prices were fixed or determinable, title or risk of loss had passed, and collection was reasonably assured. Revenue was recognized upon shipment and payments were either received in advance, or net 30 days for lenses or net 14 days for accessories. Distributor arrangements included certain perfunctory acceptance provisions and a one-year warranty, from the date of shipment, that products are free from defects in material workmanship. Under such provisions customers may reject shipments via written notifications ranging from 14-45 days or exchange defective product under warranty for the same non-defective product. We have not had any significant rejected shipments or warranty claims. We did not grant price concessions to our distributors. Effective January 1, 2018, the Company adopted the provisions of Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 606, Revenue from Contracts with Customers (“ASC 606”), using the modified retrospective transition method. Under this method, the Company recognizes revenue based on an analysis of the goods and services provided to our customers in the ordinary course. We analyze all commercial agreements to identify (i) contracts and arrangements with customers that meet the criteria for revenue recognition under the new standard (ii) identify all performance obligations under the contractual arrangement, such as the delivery of our Microlens to our customers and any other deliverable(s) as defined in a commercial arrangement (iii) the determination of the transaction price, (iv) the allocation of such pricing over the defined contractual obligations in the contract with the customer and (v) the recognition of revenue once the customer has assumed control over the contractual obligations. Control refers to the ability on the part of the customer to obtain substantially all the benefits of possession of the delivered product or service. The Company is required by ASC 606 to disaggregate revenue into categories that depict the nature, amount, timing, and uncertainty of revenue and cash flows as affected by economic factors. Currently, the Company believes these economic factors are primarily attributable to different geographic regions, under one operating segment. Refer to Note 11, Operating Segments and Geographic Information, to the Company’s consolidated financial statements for additional details of revenues by geographic region. In the future, the Company will reassess whether geographic region revenue disaggregation continues to depict the nature, amount, timing, and uncertainty of revenue and cash flows as affected by economic factors. Future assessment may be affected by, but not limited to: (i) an increase in revenue; (ii) concentration of customers; and (iii) other economic factors, in accordance with ASC 606. In the years ended December 31, 2018 and 2017 there were five and four customers, respectively, that represented 100% of total sales recognized for each year. As of December 31, 2018, the Company was not authorized to manufacture or sell any of its products or services within the United States and, as a result, all of the Company’s revenues are derived from foreign customers. The Company recognized revenues of $21,000 and $14,000 from foreign ophthalmic clinics during the years ended December 31, 2018 and 2017, respectively.
Clinical Trials	Clinical Trials In February 2015, the Company received approval from the FDA to commence enrollment of the second stage of its U.S. staged pivotal clinical trial of its Microlens involving the implantation of presbyopic patients. Enrollment for the second stage was completed in September 2015. The first staged-enrollment commenced during the first quarter of 2014, and during these trials, the Company incurred costs for patient recruiting, acquisition of clinical test equipment to be used in the trials, outside experts to read and interpret the results of the studies, third party costs to monitor the investigational sites and perform data collection activities and surgeon and patient fees in connection with the surgical procedures and follow-up visits. The Company’s policy with respect to the recognition of these costs is to record such costs as research and development expense in the consolidated statements of operations and comprehensive loss in the period in which the services are provided. The Company will evaluate the purchases of clinical test equipment, on a case by case basis, to determine if there exists an alternative use for the equipment following the clinical trials. In the event that the Company determines that there is no alternative use for the test equipment, that cost will be expensed as part of research and development expense.
Stock-Based Compensation	Stock-Based Compensation The compensation cost of stock-based awards granted to employees is measured at grant date, based on the estimated fair value of the award. The Company estimates the fair value of stock options using a Black-Scholes option pricing model. Restricted stock units awarded to employees in 2018 include a performance provision as well as a provision that the recipient must be employed as conditions of vesting. The fair value of restricted stock units issued prior to 2018 was determined using a Monte Carlo Simulation, or “MCS”, methodology, which considers the separate probabilities that of the price thresholds or market conditions will be achieved under the Restricted Stock Units Plan guidelines. Compensation expense for options granted to non-employees is determined as the fair value of consideration received or the fair value of the equity instruments issued, whichever is more reliably measured. Stock-based compensation costs are expensed on a straight-line basis over the service period. The fair value of awards granted to non-employees is remeasured each period until the related service is complete or there exists a significant disincentive not to perform the required services. Stock-based compensation costs are reflected in the accompanying statements of operations and comprehensive loss based upon the underlying employees’ roles within the Company.
Deferred Offering Costs	Deferred Offering Costs Generally, costs incurred such as legal, accounting and other professional fees including printing costs in the course of preparing for a capital raise are deferred on the balance sheet as deferred offering costs, which are eventually reclassified when the capital raise is concluded as a reduction of the proceeds of the capital raise as part of additional paid in capital. On December 5, 2016, the Company filed with the SEC a Form S-1 Registration Statement under the Securities Act of 1933 for the purpose of distributing to holders of the Company’s ordinary shares, non-transferable and non-tradeable subscription rights to purchase ordinary shares (“rights offering”). During the years ended December 31, 2018 and 2017, the Company incurred approximately $0 million and $0.3 million related to its rights offering, respectively, which was completed on March 8, 2017. Upon completion of the rights offering, the Company netted approximately $0.3 million in offering costs against the gross proceeds in shareholders’ equity as of December 31, 2017.
Income Taxes	Income Taxes As described in Note 1, the Parent completed a restructuring on October 21, 2013. As a result, some of the entities are no longer pass-through entities or were restructured as taxable entities. Provisions for federal, foreign, state, and local income taxes are calculated on pre-tax income based on current tax law and include the cumulative effect of any changes in tax rates from those used previously in determining deferred tax assets and liabilities. Deferred income tax assets and liabilities are recorded for the expected future tax consequences of temporary differences between the financial statement carrying amounts and the income tax basis of assets and liabilities. A valuation allowance is recorded to reduce net deferred income tax assets to amounts that are more likely than not to be realized.
Advertising Costs	Advertising Costs The Company incurs direct response advertising expense outside the United States in order to create awareness of the Company’s Microlens solution to presbyopia. The Company’s policy with respect to direct response advertising is to defer costs related to media and setup costs and amortize those costs to the consolidated statements of operations and comprehensive loss in the period in which the related revenue is recognized. Due to the early stages of market development and the uncertainty around the impact of advertising campaigns to-date, the Company expensed approximately $104,000, and $395,000 as part of sales and marketing expense in the consolidated statements of operations and comprehensive loss for the years ended December 31, 2018 and 2017, respectively.
Risks and Uncertainties	Risks and Uncertainties The Company’s product requires the approval of the FDA and regulatory agencies in the countries where the Company operates or expects to establish operations in the future. There is no assurance that the Company’s
Future Accounting Pronouncements	Future Accounting Pronouncements In February 2016, the FASB issued Accounting Standards Update (“ASU”) Leases (Topic 842) In February 2018, the FASB issued ASU Income Statement—Reporting Comprehensive Income (Topic 220)—Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income. In June 2018, the FASB issued ASU No. 2018-07, Compensation — Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting
Recently Adopted Accounting Standards	Recent Accounting Standards In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606). The new standard is based on the principle that revenue should be recognized to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. Topic 606 became effective for the Company in the first quarter of 2018 and allowed for full retrospective or a modified retrospective adoption approach. The Company adopted this new standard using the modified retrospective transition method In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows, which clarifies the classification of certain cash receipts and payments. The specific cash flow issues addressed by ASU 2016-15, with the objective of reducing the existing diversity in practice, are as follows: (1) Debt prepayment or debt extinguishment costs; (2) Settlement of zero-coupon debt instruments or other debt instruments with insignificant coupon interest rates; (3) Contingent consideration payments made after a business combination; (4) Proceeds from the settlement of insurance claims; (5) Proceeds from the settlement of corporate-owned life insurance policies; (6) Distributions received from equity method investees; (7) Beneficial interest in securitization transactions; and (8) Separately identifiable cash flows and application of the predominance in principle. ASU 2016-15 became effective for fiscal years beginning after December 15, 2017. The Company adopted this new standard in January 2018 and it did not have a material impact on its consolidated financial statements. In October 2016, the FASB issued ASU. 2016-16, Income Taxes (Topic 740): Intra-Entity Transfers of Assets Other than Inventory. This update requires entities to recognize the income tax consequences of an intra-entity transfer of an asset other than inventory when the transfer occurs. This update is effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. Early adoption is permitted as of the beginning of a fiscal year. The new standard must be adopted using a modified retrospective transition method, which is a cumulative-effective adjustment to retained earnings as of the beginning of the first effective reporting period. The Company adopted this new standard in January 2018 and it did not have a material impact on its consolidated financial statements. In May 2017, the FASB issued ASU 2017-09, Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting, which provides guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. This update is effective for annual reporting periods beginning after December 15, 2017. Early adoption is permitted. The Company adopted this ASU in January 2018 and it did not have a material impact on its consolidated financial statements.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2018
Accounting Policies [Abstract]
Schedule of Calculation of Basic and Diluted Loss per Share	Basic and diluted net loss per share were calculated as follows (in thousands, except share and per share data): December 31, 2018 2017 Net Loss $ (8,415 ) $ (16,998 ) USA new preferred shares dividends $ 45 $ - Net loss attributable to common shareholders $ (8,460 ) $ (16,998 ) Weighted average shares outstanding – basic and diluted 17,077,817 16,298,505 Basic and diluted net loss per share $ (0.50 ) $ (1.04 )
Schedule of Potentially Dilutive Securities Excluded from the Computation of Diluted Weighted Average Shares Outstanding	The following potentially dilutive securities were excluded from the computation of diluted weighted average shares outstanding because their inclusion would have been antidilutive: December 31, 2018 2017 Options to purchase common stock 1,129,324 1,037,964 Restricted shares 49,189 — Warrant to purchase common stock (1)(2) 16,684,792 — Series 2 Redeemable Preferred Shares and USA New Preferred Shares outstanding 5,339 — Total potentially dilutive securities excluded from denominator of the diluted earnings per share Computation 17,868,719 1,037,964 (1) Includes 1,953,125 warrants to purchase ordinary shares of Presbia PLC at a price of US$2.56 per ordinary share, granted April 12, 2018 (see Note 8). (2) Includes 14,731,667 warrants to purchase ordinary shares of Presbia PLC at a price of US$0.60 per ordinary share, granted December 10, 2018 (see Note 8).

Inventory (Tables)

Inventory (Tables)	12 Months Ended
	Dec. 31, 2018
Inventory Disclosure [Abstract]
Summary of Finished Goods Inventory	Finished goods inventory consists of the following (in thousands): December 31, 2018 2017 Lenses $ 22 $ 55 Accessories 37 72 Inventory $ 59 $ 127

Property and Equipment, net (Ta

Property and Equipment, net (Tables)	12 Months Ended
	Dec. 31, 2018
Property Plant And Equipment [Abstract]
Summary of Property and Equipment, Net	Property and equipment, net consist of the following (in thousands): December 31, 2018 2017 Office equipment and computers $ 52 $ 79 Leasehold improvements 189 214 Production equipment and facilities 760 802 Software 42 62 Furniture and vehicles 99 237 1,142 1,394 Less: accumulated depreciation (775 ) (917 ) Property and equipment, net $ 367 $ 477

Note Payable (Tables)

Note Payable (Tables)	12 Months Ended
	Dec. 31, 2018
Debt Disclosure [Abstract]
Summary of Note Payable	Note payable is summarized as follows (in thousands): December 31, 2018 2017 Noninterest bearing note payable to Neoptics A.G. $ — $ 518 Less present value discount — (38 ) Note payable, net — 480 Less current portion — 480 Note payable, long term $ — $ —

Secured Debt with Related Par_2

Secured Debt with Related Party (Tables)	12 Months Ended
	Dec. 31, 2018
Class Of Stock Disclosures [Abstract]
Schedule of Secured Debt with Related Party	Secured debt with related party consisted of the following as of the dates set forth below (in thousands): December 31, 2018 2017 Secured debt with related party $ 3,520 $ — Less current portion (20 ) — Secured debt with related party, long term 3,500 — Less unamortized transaction costs (1,585 ) — Secured debt with related party, net $ 1,915 $ —

Other Current Liabilities (Tabl

Other Current Liabilities (Tables)	12 Months Ended
	Dec. 31, 2018
Other Liabilities Current [Abstract]
Summary of Other Current Liabilities	Other current liabilities consist of the following as of the dates set forth below (in thousands): December 31, 2018 2017 Accrued payroll and severance related $ 89 352 Accrued professional fees 108 109 Accrued clinical expense 49 125 Accrued deferred rent expense — 236 Accrued other expense 53 46 Income tax payable 2 283 $ 301 $ 1,151

Equity Based Awards (Tables)

Equity Based Awards (Tables)	12 Months Ended
	Dec. 31, 2018
Share-Based Compensation Expense Included in Consolidated Statements of Operations and Comprehensive Loss	The following table shows share-based compensation expense based upon all equity awards issued by Presbia PLC included in the Consolidated Statements of Operations and Comprehensive Loss for the years ended December 31, 2018 and 2017. The Company recorded a credit of $547,000 and $970,000 as a result of the reversal of stock-based compensation for participants whose relationship with the Company terminated in the years ended December 31, 2018 and 2017, respectively. Pursuant to the Services Agreement with OCV Management, LLC (See note 8) approximately $250,000 and $12,000 was recorded as stock-based compensation expense as part of general and administrative in the following table for the fiscal years ended December 31, 2018 and 2017, respectively. Year Ended December 31, 2018 2017 Research and development $ (136 ) $ 251 General and administrative 547 951 Sales and marketing 119 (34 ) $ 530 $ 1,168
Schedule of Option Activity	The following table sets forth the Company’s option activity for the year ended December 31, 2018: Number of Presbia PLC Shares Weighted Average Exercise Price Per Share Aggregate Intrinsic Value Balance, January 1, 2018 849,100 $ 9.77 — Granted 939,172 $ 1.73 — Exercised — $ — — Forfeited/cancelled/expired (174,600 ) $ 8.38 — Balance, December 31, 2018 1,613,672 $ 5.24 — Vested, December 31, 2018 656,000 $ 9.84 — Non Vested, December 31, 2018 957,672 $ 2.10 — Exercisable, December 31, 2018 653,000 $ 9.84 —
Schedule of Restricted Shares Activity	The following table sets forth the Company’s restricted share activity for the year ended December 31, 2018: Unvested Number of Shares Weighted Average Fair Value per Share Balance, December 31, 2017 134,367 $ 3.78 Granted 35,303 $ 2.27 Vested (127,228 ) $ 3.23 Forfeited/cancelled — $ — Unvested, December 31, 2018 42,442 $ 5.47
Schedule of RSU Activity	The following table sets forth the Company’s RSU activity for the year ended December 31, 2018: Unvested Number of Shares Weighted Average Fair Value per Share Balance, December 31, 2017 739,000 $ 2.09 Granted 170,000 $ 2.00 Vested — $ — Forfeited/cancelled (409,000 ) $ 2.95 Unvested, December 31, 2018 500,000 $ 1.36
Non-employee options [Member]
Schedule of Black-Scholes Valuation Model Assumptions for Estimating the Fair Value of Share-Based Compensation	During the years ended December 31, 2018 and 2017, the Company did not grant options to non-employee consultants and medical advisors. Grants issued prior to 2017 were fully vested as of December 31, 2018. In contrast to the determination of the fair value of options granted to employees, which are determined based upon the grant-date assumptions and applying the Black-Scholes model, the fair values for non-employee options and the related stock-based compensation expense are remeasured each financial reporting period based upon the assumptions applicable on the dates in which the financial statements are prepared, which are disclosed in the following table: Year Ended December 31, 2018 2017 Stock price per share $0.85 -$1.95 $1.31 -$2.83 Expected term 6.6 - 7.4 Yrs. 7.7 - 8.3 Yrs. Volatility 72.9% - 77.3% 69.3% - 85.8% Dividends — — Risk-free rate 2.6% - 2.8% 2.2% - 2.4%

Related Party Transactions (Tab

Related Party Transactions (Tables)	12 Months Ended
	Dec. 31, 2018
Related Party Transactions [Abstract]
Schedule of Amounts Due to Related Parties	The following table sets forth the amounts due to related parties reflected in the accompanying consolidated balance sheets (in thousands): Year Ended December 31, 2018 2017 Payable to related parties-current: Management services provided by related parties $ 39 $ 35 Less current portion 39 23 Management services provided by related parties, long-term $ — $ 12

Operating Segments and Geogra_2

Operating Segments and Geographic Information (Tables)	12 Months Ended
	Dec. 31, 2018
Segment Reporting [Abstract]
Schedule of Revenues Generated from External Customers and Long-lived Assets by Area	The following table sets forth the Company’s revenues generated from external customers located in foreign countries and long-lived assets by area (in thousands): Year Ended December 31, Revenues 2018 2017 Canada $ — $ 1 Ireland — 14 Italy 1 — The Netherlands — (1 ) Germany 20 — Total $ 21 $ 14 Year Ended December 31, Long-lived Assets 2018 2017 U.S. 346 453 Foreign 21 24 Total $ 367 $ 477

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2018
Commitments And Contingencies Disclosure [Abstract]
Schedule of Annual Base Rental Cost Over the Term of the Leases	The following table shows the annual base rental cost over the term of the leases (in thousands). Years Ended December 31, Obligations Under Facility Leases 2019 $ 292 2020 298 2021 287 2022 119 Total $ 996

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Schedule of Provision for Income Taxes	The provision for income taxes consists of the following (in thousands): Year Ended December 31, 2018 2017 Current provision: Federal $ — $ — State 2 2 Foreign (237 ) 243 Total current $ (235 ) $ 245 Deferred provision Federal (1,103 ) (3,335 ) State — — Foreign (59 ) (1,065 ) Total deferred (1,162 ) (2,270 ) Valuation allowance 1,162 2,270 Total deferred — — Total income tax (benefit) provision $ (235 ) $ 245
Schedule of Reconciliation of Federal Statutory Rate to Effective Rate	A reconciliation of the federal statutory rate to the effective rate is as follows: Year Ended December 31, 2018 2017 Expected income tax benefit at federal statutory rate 21.0 % 35.0 % State tax provision, net of federal benefit (0.0 %) (0.0 %) Foreign rate differential (8.1 %) (15.0 %) Nondeductible expenses (0.0 %) (0.1 %) Foreign Tax 2.8 % (1.4 %) Change in valuation allowance (13.5 %) (4.2 %) Effect of Change in Tax Rate 0.0 % (9.3 %) Other 0.6 % (6.5 %) Income tax provision (benefit) 2.7 % (1.4 %)
Components of Deferred Tax Assets	The components of the Company’s deferred tax assets are summarized as follows (in thousands): Year Ended December 31, 2018 2017 Deferred tax assets: Net operating loss carryforwards $ 6,279 $ 5,019 Accrued expenses 47 31 Stock based compensation 0 0 Deferred tax assets 6,326 5,050 Valuation allowance (6,310 ) (5,033 ) Net deferred tax assets 16 17 Deferred tax liabilities: Depreciation (16 ) (17 ) Total deferred tax liabilities (16 ) (17 ) Net deferred tax asset $ — $ —

Basis of Presentation and Des_3

Basis of Presentation and Description of the Business - Additional Information (Detail)	Dec. 10, 2018USD ($)$ / sharesshares	Apr. 12, 2018USD ($)$ / sharesshares	Aug. 03, 2015shares	Feb. 03, 2015USD ($)$ / sharesshares	Jan. 14, 2015USD ($)$ / sharesshares	Nov. 30, 2014USD ($)	Feb. 06, 2014USD ($)shares	Feb. 06, 2014EUR (€)€ / sharesshares	Dec. 31, 2018USD ($)Country$ / shares	Dec. 31, 2017USD ($)$ / shares
Basis Of Presentation [Line Items]
Date of incorporation									Feb. 6, 2014
Number of shares, value										$ 10,534,000
Ordinary shares, par value | $ / shares									$ 0.001
Capitalization of amounts due to Parent per 2014 and 2015 Debt Conversions					$ 1,600,000	$ 23,500,000
Proceeds from sale of preferred shares, net of costs									$ 4,890,000
Number of ordinary shares covered by warrants | shares	14,731,667	1,953,125
Exercise price | $ / shares	$ 0.60	$ 2.56
Number of country in which company is authorized to sell, market and perform procedure | Country									40
Accumulated deficit									$ 96,762,000	$ 88,302,000
Richard Ressler [Member]
Basis Of Presentation [Line Items]
Legal and professional fees	$ 200,000	$ 100,000
Proceeds from sale of preferred shares, net of costs		$ 4,900,000
Number of ordinary shares covered by warrants | shares	14,731,667	1,953,125
Exercise price | $ / shares	$ 0.60	$ 2.56
Secured loan aggregate principle amount	$ 3,500,000
Net proceeds from secured loan	$ 3,300,000
Richard Ressler [Member] | Preferred Stock [Member]
Basis Of Presentation [Line Items]
Number of shares issued | shares		100
Number of shares, value		$ 5,000,000
Legal and professional fees		100,000
Proceeds from sale of preferred shares, net of costs		$ 4,900,000
IPO [Member]
Basis Of Presentation [Line Items]
Ordinary shares, price per share | $ / shares				$ 10
Gross proceeds from issuance of stock				$ 41,700,000
Underwriting discounts and commission costs				2,900,000
Other issuance costs				2,000,000
Net proceeds from issuance of stock				$ 36,800,000
2015 Capital Contribution [Member]
Basis Of Presentation [Line Items]
Number of shares issued | shares					9,166,667
Ordinary shares, par value | $ / shares					$ 0.01
Ordinary Shares [Member]
Basis Of Presentation [Line Items]
Ordinary shares, par value | $ / shares									$ 0.001	$ 0.001
Ordinary Shares [Member] | IPO [Member]
Basis Of Presentation [Line Items]
Number of shares issued | shares				4,166,667
Presbia Holdings [Member]
Basis Of Presentation [Line Items]
Percentage of ownership interests								100.00%
Ordinary shares, par value | € / shares								€ 1
Presbia Holdings [Member] | Ordinary Shares [Member]
Basis Of Presentation [Line Items]
Number of shares issued | shares							40,000	40,000
Number of shares, value							$ 54,000	€ 40,000
Presbia Holdings [Member] | Ordinary Shares [Member] | IPO [Member]
Basis Of Presentation [Line Items]
Number of shares issued | shares				500,000
Presbia Holdings [Member] | Orchard Capital Corporation
Basis Of Presentation [Line Items]
Number of shares issued | shares			9,666,667
Presbia USA, Inc [Member] | Richard Ressler [Member] | Preferred Stock [Member]
Basis Of Presentation [Line Items]
Number of shares issued | shares	5,239	4,900
Shares exchanged under securities purchase and exchange agreement | shares	4,900
Dividends exchanged under securities purchase and exchange agreement | shares	339

Summary of Significant Accoun_3

Summary of Significant Accounting Policies - Additional Information (Detail) SFr in Millions	Aug. 02, 2016USD ($)Installment	Aug. 02, 2016CHF (SFr)Installment	Dec. 31, 2018USD ($)SegmentCustomer	Dec. 31, 2017USD ($)Customer
Significant Accounting Policies [Line Items]
Number of operating segment | Segment			1
Short-term investment instruments			$ 0	$ 0
Expiration period of each lens			5 years
Payment to acquire patents and patent applications				125,000
Net carrying amount			$ 1,344,000	1,479,000
Impairment charges			0	0
Software capitalized cost			0	0
Amortization expenses of capitalized software			$ 1,000	$ 15,000
Warranty period, from the date of shipment			1 year
Number of customers | Customer			5	4
Revenues			$ 21,000	$ 14,000
Income tax rate			21.00%	35.00%
ASU 2016-02 [Member]
Significant Accounting Policies [Line Items]
Expected leasehold liabilities to be recognized			$ 671,000
Expected right of use assets to be recognized			671,000
Rights Offering [Member]
Significant Accounting Policies [Line Items]
Rights offering costs			$ 0	$ 300,000
Payment of offering costs				$ 300,000
Sales [Member] | Customer Concentration [Member]
Significant Accounting Policies [Line Items]
Concentration risk, percentage			100.00%	100.00%
Lenses [Member]
Significant Accounting Policies [Line Items]
Payments collection period			30 days
Accessories [Member]
Significant Accounting Policies [Line Items]
Payments collection period			14 days
Laser Center Revenues [Member] | Foreign [Member]
Significant Accounting Policies [Line Items]
Revenues			$ 21,000	$ 14,000
Patents [Member]
Significant Accounting Policies [Line Items]
Useful life			12 years 4 months
Intangible asset end of useful life			Nov. 25, 2028
Amortization expense			$ 136,000
Net carrying amount			1,344,000
Neoptics AG [Member]
Significant Accounting Policies [Line Items]
Aggregate purchase price of assets	$ 1,500,000	SFr 1.5
Number of equal installments | Installment	3	3
Payment to acquire patents and patent applications			500,000
Estimated amortization expense, 2019			135,000
Estimated amortization expense, 2020			135,000
Estimated amortization expense, 2021			135,000
Estimated amortization expense, 2022			$ 135,000
Neoptics AG [Member] | First Installment [Member]
Significant Accounting Policies [Line Items]
Asset purchase price payable installment due date	Aug. 2, 2016	Aug. 2, 2016
Neoptics AG [Member] | Second Installment [Member]
Significant Accounting Policies [Line Items]
Asset purchase price payable installment due date	Dec. 31, 2017	Dec. 31, 2017
Neoptics AG [Member] | Third Installment [Member]
Significant Accounting Policies [Line Items]
Asset purchase price payable installment due date	Dec. 31, 2018	Dec. 31, 2018
Minimum [Member]
Significant Accounting Policies [Line Items]
Estimated life of property and equipment			3 years
Written notification period to reject shipments by customers			14 days
Maximum [Member]
Significant Accounting Policies [Line Items]
Estimated life of property and equipment			10 years
Written notification period to reject shipments by customers			45 days
Number of customers | Customer			4	4
General and Administrative Expense [Member]
Significant Accounting Policies [Line Items]
Aggregate foreign exchange loss			$ 12,000	$ 59,000
Selling and Marketing Expense [Member]
Significant Accounting Policies [Line Items]
Advertising costs			$ 104,000	$ 395,000

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Schedule of Calculation of Basic and Diluted Loss per Share (Detail) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Basic and diluted net loss per share
Net Loss	$ (8,415)	$ (16,998)
USA new preferred shares dividends	45
Net loss attributable to common shareholders	$ (8,460)	$ (16,998)
Weighted average shares outstanding – basic and diluted	17,077,817	16,298,505
Basic and diluted net loss per share	$ (0.50)	$ (1.04)
USA Preferred Shares [Member]
Basic and diluted net loss per share
USA new preferred shares dividends	$ 45

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities Excluded from the Computation of Diluted Weighted Average Shares Outstanding (Details) - shares	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Total potentially dilutive securities excluded from denominator of the diluted earnings per share Computation	17,868,719	1,037,964
Options to Purchase Common Stock [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Total potentially dilutive securities excluded from denominator of the diluted earnings per share Computation	1,129,324	1,037,964
Restricted Shares [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Total potentially dilutive securities excluded from denominator of the diluted earnings per share Computation	49,189
Warrant to Purchase Common Stock [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Total potentially dilutive securities excluded from denominator of the diluted earnings per share Computation	16,684,792
Series 2 Redeemable Preferred Shares and USA New Preferred Shares Outstanding [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Total potentially dilutive securities excluded from denominator of the diluted earnings per share Computation	5,339

Summary of Significant Accoun_6

Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities Excluded from the Computation of Diluted Weighted Average Shares Outstanding (Parenthetical) (Details) - $ / shares	Dec. 10, 2018	Apr. 12, 2018
Earnings Per Share [Abstract]
Number of ordinary shares covered by warrants	14,731,667	1,953,125
Exercise price	$ 0.60	$ 2.56

Inventory - Additional Informat

Inventory - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Inventory Disclosure [Abstract]
Inventory write-downs reflecting excess quantities on hand recognized	$ 45	$ 90

Inventory - Summary of Finished

Inventory - Summary of Finished Goods Inventory (Detail) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Inventory [Line Items]
Inventory	$ 59	$ 127
Lenses [Member]
Inventory [Line Items]
Inventory	22	55
Accessories [Member]
Inventory [Line Items]
Inventory	$ 37	$ 72

Property and Equipment, net - S

Property and Equipment, net - Summary of Property and Equipment, Net (Detail) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 1,142	$ 1,394
Less: accumulated depreciation	(775)	(917)
Property and equipment, net	367	477
Office equipment and computers [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	52	79
Leasehold improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	189	214
Production equipment and facilities [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	760	802
Software [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	42	62
Furniture and vehicles [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 99	$ 237

Property and Equipment, net - A

Property and Equipment, net - Additional Information (Detail) - USD ($)	1 Months Ended	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2018	Dec. 31, 2017
Property, Plant and Equipment [Line Items]
Depreciation and amortization expense		$ 109,000	$ 322,000
Furniture and Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Unrecognized depreciation	$ 67,000
Engineering Tools, Molds and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Unrecognized depreciation	$ 52,000

Note Payable - Summary of Note

Note Payable - Summary of Note Payable (Detail) $ in Thousands	Dec. 31, 2017USD ($)
Debt Instrument [Line Items]
Note payable, net	$ 480
Less current portion	480
Note Payable To Neoptics AG [Member]
Debt Instrument [Line Items]
Noninterest bearing note payable to Neoptics A.G.	518
Less present value discount	$ (38)

Note Payable - Additional Infor

Note Payable - Additional Information (Detail) SFr in Millions	Aug. 02, 2016USD ($)Installment	Aug. 02, 2016CHF (SFr)Installment	Dec. 31, 2018USD ($)	Dec. 31, 2017USD ($)
Debt Instrument [Line Items]
Note payable, current portion				$ 480,000
Payment to acquire patents and patent applications				125,000
Neoptics AG [Member]
Debt Instrument [Line Items]
Aggregate purchase price of assets	$ 1,500,000	SFr 1.5
Number of equal installments | Installment	3	3
Payment description			No interest and payable in three equal installments on each of August 2, 2016, December 31, 2017 and December 31, 2018.
Loan discount rate			9.00%
Note payable, current portion				480,000
Unamortized discount				$ 38,000
Payment to acquire patents and patent applications			$ 500,000
Neoptics AG [Member] | First Installment [Member]
Debt Instrument [Line Items]
Interest payable	$ 0
Asset purchase price payable installment due date	Aug. 2, 2016	Aug. 2, 2016
Neoptics AG [Member] | Second Installment [Member]
Debt Instrument [Line Items]
Interest payable	$ 0
Asset purchase price payable installment due date	Dec. 31, 2017	Dec. 31, 2017
Neoptics AG [Member] | Third Installment [Member]
Debt Instrument [Line Items]
Interest payable	$ 0
Asset purchase price payable installment due date	Dec. 31, 2018	Dec. 31, 2018

Secured Debt with Related Par_3

Secured Debt with Related Party - Additional Information (Detail) - USD ($)	Dec. 10, 2018	Apr. 12, 2018	Dec. 31, 2018	Dec. 31, 2018
Related Party Transaction [Line Items]
Exercise price	$ 0.60	$ 2.56
Number of ordinary shares covered by warrants	14,731,667	1,953,125
Aggregate fair value of the warrant issued			$ 2,837,000	$ 2,837,000
Secured debt with related party			3,520,000	3,520,000
Richard Ressler [Member]
Related Party Transaction [Line Items]
Secured loan aggregate principle amount	$ 3,500,000
Legal and professional fees	200,000	$ 100,000
Net proceeds from secured loan	3,300,000
Aggregate amount of securities involved in financing transactions	$ 8,800,000
Exercise price	$ 0.60	$ 2.56
Number of ordinary shares covered by warrants	14,731,667	1,953,125
Unamortized discount			1,400,000	1,400,000
Aggregate fair value of the warrant issued	$ 3,523,000	$ 3,126,000	2,837,000	2,837,000
Termination date of warrant	5 years
Average stock price volatility rate	73.95%
Adjustments to additional paid in capital				2,100,000
Richard Ressler [Member] | Measurement Input, Risk Free Interest Rate [Member]
Related Party Transaction [Line Items]
Risk-free interest rate	0.0270
Richard Ressler [Member] | Black-Scholes [Member]
Related Party Transaction [Line Items]
Aggregate fair value of the warrant issued			$ 3,500,000	$ 3,500,000
Richard Ressler [Member] | Secured Promissory Note [Member]
Related Party Transaction [Line Items]
Legal and professional fees	$ 200,000
Secured promissory note maturity term				5 years
Right to call loan earliest period				2 years
Annual interest rate			10.00%	10.00%
Unamortized discount	1,600,000
Warrant issued	1,400,000
Fair value of ordinary shares			5,833,333	5,833,333
Accretion period to loan for unamortized transaction costs and direct costs				5 years
Secured debt with related party			$ 3,520,000	$ 3,520,000
Accrued interest			$ 20,000
Richard Ressler [Member] | Private Placement [Member]
Related Party Transaction [Line Items]
Secured loan aggregate principle amount	3,500,000
Legal and professional fees	200,000
Net proceeds from secured loan	3,300,000
Orginal proceeds of preferred shares	5,000,000
Accrued dividends	$ 300,000
Richard Ressler [Member] | Preferred Stock [Member]
Related Party Transaction [Line Items]
Legal and professional fees		$ 100,000
Number of shares issued		100
Richard Ressler [Member] | Preferred Stock [Member] | Presbia USA, Inc [Member]
Related Party Transaction [Line Items]
Number of shares issued	5,239	4,900
Richard Ressler [Member] | Preferred Stock [Member] | Private Placement [Member]
Related Party Transaction [Line Items]
Number of shares issued	100
Richard Ressler [Member] | Preferred Stock [Member] | Private Placement [Member] | Presbia USA, Inc [Member]
Related Party Transaction [Line Items]
Number of shares issued	4,900
Preferred shares dividends	339
Richard Ressler [Member] | Series 2 Redeemable Preferred Shares [Member]
Related Party Transaction [Line Items]
Number of shares issued	100
Shares redeemed	100
Richard Ressler [Member] | USA Preferred Shares [Member] | Presbia USA, Inc [Member]
Related Party Transaction [Line Items]
Shares redeemed	5,239

Secured Debt with Related Par_4

Secured Debt with Related Party - Summary of Secured Debt with Related Party (Detail) $ in Thousands	Dec. 31, 2018USD ($)
Class Of Stock Disclosures [Abstract]
Secured debt with related party	$ 3,520
Less current portion	(20)
Secured debt with related party, long term	3,500
Less unamortized transaction costs	(1,585)
Secured debt with related party, net	$ 1,915

Other Current Liabilities - Sum

Other Current Liabilities - Summary of Other Current Liabilities (Detail) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Other Liabilities Current [Abstract]
Accrued payroll and severance related	$ 89	$ 352
Accrued professional fees	108	109
Accrued clinical expense	49	125
Accrued deferred rent expense		236
Accrued other expense	53	46
Income tax payable	2	283
Total	$ 301	$ 1,151

Shareholders' Equity - Addition

Shareholders' Equity - Additional Information (Detail)	Dec. 10, 2018USD ($)$ / sharesshares	Apr. 12, 2018USD ($)$ / sharesshares	Dec. 14, 2017USD ($)	Dec. 31, 2018USD ($)$ / sharesshares	Dec. 31, 2018USD ($)$ / sharesshares	Dec. 31, 2017USD ($)$ / sharesshares	Jan. 02, 2019shares	Dec. 31, 2018EUR (€)€ / sharesshares	Apr. 30, 2018USD ($)	Jan. 02, 2018$ / shares	Dec. 31, 2017€ / shares	Aug. 31, 2015shares	Jan. 14, 2015shares	Dec. 31, 2014USD ($)$ / sharesshares	Dec. 31, 2014€ / shares
Class Of Stock [Line Items]
Ordinary shares, value authorized				$ 400,000	$ 400,000			€ 40,000
Ordinary shares, shares authorized				350,000,000	350,000,000			350,000,000
Ordinary shares, par value | $ / shares				$ 0.001	$ 0.001
Preferred shares, shares authorized				50,000,000	50,000,000			50,000,000
Preferred shares, par value | $ / shares				$ 0.001	$ 0.001
Deferred ordinary shares, par value | (per share)				$ 1.35	$ 1.35	$ 1.35		€ 1			€ 1			$ 1.35	€ 1
Aggregate fair value of the warrant issued | $				$ 2,837,000	$ 2,837,000
Exercise price | $ / shares	$ 0.60	$ 2.56
Adjustment of warrants | $				288,000
Preferred shares increased value | $				2,053,000
Deferred Ordinary shares | $				$ 54,000	$ 54,000	$ 54,000								$ 54,000
Deferred ordinary shares, shares authorized				39,994	39,994	39,994		39,994						40,000
Deferred ordinary shares, shares issued				39,994	39,994	39,994		39,994					40,000
Cash payment for ordinary shareholders upon winding up | $					$ 5,000,000
Preferred shares, dividends | $					45,000
Number of ordinary shares covered by warrants	14,731,667	1,953,125
Preferred shares aggregate purchase price | $						$ 10,534,000
Proceeds from sale of preferred shares, net of costs | $					$ 4,890,000
Agregate fair value of preferred shares issued | $									$ 1,765,000
Richard Ressler [Member]
Class Of Stock [Line Items]
Deferred Ordinary Shares Transferred												39,994
Deferred Ordinary Shares [Member]
Class Of Stock [Line Items]
Ordinary shares, shares authorized				40,000	40,000			40,000
Series 2 Redeemable Preferred Shares [Member]
Class Of Stock [Line Items]
Preferred shares, shares authorized				50,000,000	50,000,000	50,000,000		50,000,000
Preferred shares, par value | $ / shares				$ 0.001	$ 0.001	$ 0.001
Preferred shares, shares issued				100	100	0		100
Preferred shares, shares outstanding				100	100	0		100
USA Preferred Shares [Member]
Class Of Stock [Line Items]
Preferred shares, shares authorized				8,000	8,000	8,000		8,000
Preferred shares, par value | $ / shares				$ 0.01	$ 0.01	$ 0.01
Preferred shares, shares issued				5,239	5,239	0		5,239
Preferred shares, shares outstanding				5,239	5,239	0		5,239
Preferred shares, dividend rate					15.00%
Preferred shares, dividends | $					$ 45,000
Richard Ressler [Member]
Class Of Stock [Line Items]
Aggregate fair value of the warrant issued | $	$ 3,523,000	$ 3,126,000		$ 2,837,000	$ 2,837,000
Exercise price | $ / shares	$ 0.60	$ 2.56
Adjustment of warrants | $				288,000
Preferred shares increased value | $				$ 2,053,000
Unamortized transaction costs | $	$ 1,395,000
Number of ordinary shares covered by warrants	14,731,667	1,953,125
Legal and professional fees | $	$ 200,000	$ 100,000
Proceeds from sale of preferred shares, net of costs | $		$ 4,900,000
Richard Ressler [Member] | Preferred Shares [Member]
Class Of Stock [Line Items]
Preferred shares issued		100
Preferred shares aggregate purchase price | $		$ 5,000,000
Legal and professional fees | $		100,000
Proceeds from sale of preferred shares, net of costs | $		4,900,000
Number of shares retired	100
Richard Ressler [Member] | Series 2 Redeemable Preferred Shares [Member]
Class Of Stock [Line Items]
Preferred shares issued	100
Richard Ressler [Member] | Series 2 Redeemable Preferred Shares [Member]
Class Of Stock [Line Items]
Preferred shares issued	100
Preferred shares aggregate purchase price | $	$ 100,000
Richard Ressler [Member] | Presbia P L C
Class Of Stock [Line Items]
Aggregate fair value of the warrant issued | $	$ 14,731,667	$ 1,953,125
Exercise price | $ / shares	$ 0.60	$ 2.56
Richard Ressler [Member] | Presbia USA, Inc [Member]
Class Of Stock [Line Items]
Preferred shares dividends redeemed	339
Richard Ressler [Member] | Presbia USA, Inc [Member] | Preferred Shares [Member]
Class Of Stock [Line Items]
Preferred shares issued	5,239	4,900
Shares exchanged under securities purchase and exchange agreement	4,900
Dividends exchanged under securities purchase and exchange agreement	339
Number of shares retired	4,900
OCV Management, LLC [Member] | Accessories [Member]
Class Of Stock [Line Items]
Notice period for agreement termination			30 days
Annual fee payable | $			$ 250,000
Closing price of share | $ / shares										$ 3.45
OCV Management, LLC [Member] | Accessories [Member] | Subsequent Event [Member]
Class Of Stock [Line Items]
Ordinary shares, shares issued							72,464

Equity Based Awards - Additiona

Equity Based Awards - Additional Information (Detail) - USD ($)	Jan. 14, 2015	Dec. 31, 2018	Dec. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock based compensation charge reversal		$ 547,000	$ 970,000
Stock based compensation expense		$ 530,000	$ 1,168,000
Options granted		939,172
Non-employee consultants and medical advisors [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Options granted		0	0
Employee Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Options granted		0	0
Employee Options [Member] | Employee and Directors [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Options granted		939,172	0
Employee Options [Member] | Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Award expiration period		6 years 9 months
Awards vesting period		5 years
Employee Options [Member] | Director [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Award expiration period		6 years 9 months
Awards vesting period		1 year
Restricted shares [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Restricted shares granted		35,303	89,166
Unrecognized compensation expense, weighted average period of recognition		1 year 7 months 6 days	1 year 7 months 6 days
Unrecognized compensation expense related to restricted shares/RSUs		$ 200,000	$ 200,000
Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Restricted shares granted		170,000
Unrecognized compensation expense, weighted average period of recognition		1 year 10 months 24 days	2 years
Unrecognized compensation expense related to restricted shares/RSUs		$ 400,000	$ 7,300,000
Employee and non-employee options [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Unrecognized compensation expense related to options		$ 900,000	$ 500,000
Unrecognized compensation expense, weighted average period of recognition		1 year 10 months 24 days	1 year 6 months
General and Administrative Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock based compensation expense		$ 547,000	$ 951,000
General and Administrative Expense [Member] | OCV Management, LLC [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock based compensation expense		$ 250,000	$ 12,000
Over five year period [Member] | Employee Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Generally vesting percentage for annual		20.00%
Presbia Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Award expiration period	10 years
Ordinary shares authorized for issuance	2,500,000
Ordinary shares available for future grants and awards		186,314
Awards vesting period	5 years
Award expiration date		Jan. 14, 2025
Presbia Incentive Plan [Member] | Over five year period [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Generally vesting percentage for annual	20.00%

Equity Based Awards - Share-Bas

Equity Based Awards - Share-Based Compensation Expense Included in Consolidated Statements of Operations and Comprehensive Loss (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Share-based compensation expense	$ 530	$ 1,168
Research and development [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Share-based compensation expense	(136)	251
General and administrative [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Share-based compensation expense	547	951
Sales and marketing [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Share-based compensation expense	$ 119	$ (34)

Equity Based Awards - Schedule

Equity Based Awards - Schedule of Option Activity (Detail)	12 Months Ended
	Dec. 31, 2018$ / sharesshares
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Number of Presbia PLC Shares, Beginning Balance | shares	849,100
Number of shares, Granted | shares	939,172
Number of Presbia PLC Shares, Forfeited/cancelled/expired | shares	(174,600)
Number of Presbia PLC Shares, Ending Balance | shares	1,613,672
Number of Presbia PLC Shares, Vested | shares	656,000
Number of Presbia PLC Shares, Non Vested | shares	957,672
Number of Presbia PLC Shares, Exercisable | shares	653,000
Weighted Average Exercise Price Per Share, Beginning Balance | $ / shares	$ 9.77
Weighted Average Exercise Price Per Share, Granted | $ / shares	1.73
Weighted Average Exercise Price Per Share, Forfeited/cancelled/expired | $ / shares	8.38
Weighted Average Exercise Price Per Share, Ending Balance | $ / shares	5.24
Weighted Average Exercise Price Per Share, Vested | $ / shares	9.84
Weighted Average Exercise Price Per Share, Non Vested | $ / shares	2.10
Weighted Average Exercise Price Per Share, Exercisable | $ / shares	$ 9.84

Equity Based Awards - Schedul_2

Equity Based Awards - Schedule of Black-Scholes Valuation Model Assumptions for Estimating the Fair Value of Share-Based Compensation (Detail) - Non-employee options [Member] - $ / shares	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Volatility minimum	72.90%	69.30%
Volatility maximum	77.30%	85.80%
Risk-free rate minimum	2.60%	2.20%
Risk-free rate maximum	2.80%	2.40%
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock price per share	$ 0.85	$ 1.31
Expected term	6 years 7 months 6 days	7 years 8 months 12 days
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock price per share	$ 1.95	$ 2.83
Expected term	7 years 4 months 24 days	8 years 3 months 18 days

Equity Based Awards - Schedul_3

Equity Based Awards - Schedule of Restricted Share Activity (Detail) - Restricted shares [Member] - $ / shares	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Unvested Number of Shares, Beginning Balance	134,367
Unvested Number of Shares, Granted	35,303	89,166
Unvested Number of Shares, Vested	(127,228)
Unvested Number of Shares, Ending Balance	42,442	134,367
Weighted Average Fair Value per Share, Beginning Balance	$ 3.78
Weighted Average Fair Value per Share, Granted	2.27
Weighted Average Fair Value per Share, Vested	3.23
Weighted Average Fair Value per Share, Ending Balance	$ 5.47	$ 3.78

Equity Based Awards - Schedul_4

Equity Based Awards - Schedule of RSU Activity (Detail) - Restricted Stock Units [Member]	12 Months Ended
	Dec. 31, 2018$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Unvested Number of Shares, Beginning Balance | shares	739,000
Unvested Number of Shares, Granted | shares	170,000
Unvested Number of Shares, Forfeited/cancelled | shares	(409,000)
Unvested Number of Shares, Ending Balance | shares	500,000
Weighted Average Fair Value per Share, Beginning Balance | $ / shares	$ 2.09
Weighted Average Fair Value per Share, Granted | $ / shares	2
Weighted Average Fair Value per Share, Forfeited/cancelled | $ / shares	2.95
Weighted Average Fair Value per Share, Ending Balance | $ / shares	$ 1.36

Related Party Transactions - Sc

Related Party Transactions - Schedule of Amounts Due to Related Parties (Detail) - Management services [Member] - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Payable to related parties-current:
Management services provided by related parties	$ 39	$ 35
Less current portion	$ 39	23
Management services provided by related parties, long-term		$ 12

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Detail) - USD ($)	Dec. 10, 2018	Apr. 12, 2018	Dec. 14, 2017	Dec. 31, 2018	Dec. 31, 2017	Jan. 02, 2019
Related Party Transaction [Line Items]
Due to related parties				$ 39,000	$ 23,000
Preferred shares aggregate purchase price					10,534,000
Number of ordinary shares covered by warrants	14,731,667	1,953,125
Exercise price	$ 0.60	$ 2.56
Orchard Capital Corporation
Related Party Transaction [Line Items]
General and administrative expense				5,000	14,000
Orchard Capital Corporation | Management and Accounting Services [Member]
Related Party Transaction [Line Items]
Due to related parties				1,000	3,000
C I M Group L P
Related Party Transaction [Line Items]
Due to related parties				26,000	19,000
Charges incurred				$ 38,000	$ 37,000
OCV Management, LLC [Member] | Accessories [Member]
Related Party Transaction [Line Items]
Notice period for agreement termination			30 days
Annual fee payable			$ 250,000
Related party transaction, terms				On December 14, 2017, the Company concluded a services agreement with OCV Management, LLC, a related party co-founded by Mr. Ressler and Mark Yung (see Note 8), for the purpose of providing management services for the Company for the period commencing December 14, 2017 until terminated upon thirty (30) days’ prior written notice by either of the parties. OCV Management, LLC will receive an annual fee of $250,000, payable annually in arrears. The obligation will be settled in the form of ordinary shares issued by the Company in a private offering. For 2018, the number of shares to be issued was determined by dividing $250,000 by the closing price on January 2, 2018 and 72,464 shares were issued on January 2, 2019. The program continues into 2019.
OCV Management, LLC [Member] | Accessories [Member] | Subsequent Event [Member]
Related Party Transaction [Line Items]
Ordinary shares, shares issued						72,464
Richard Ressler [Member]
Related Party Transaction [Line Items]
Number of ordinary shares covered by warrants	14,731,667	1,953,125
Exercise price	$ 0.60	$ 2.56
Warrant exercisable period		5 years
Secured loan aggregate principle amount	$ 3,500,000
Richard Ressler [Member] | Series 2 Redeemable Preferred Shares [Member]
Related Party Transaction [Line Items]
Preferred shares issued	100
Preferred shares aggregate purchase price	$ 100,000
Richard Ressler [Member] | Preferred Shares [Member]
Related Party Transaction [Line Items]
Preferred shares issued		100
Preferred shares aggregate purchase price		$ 5,000,000
Number of shares retired	100
Richard Ressler [Member] | Preferred Shares [Member] | Presbia USA, Inc [Member]
Related Party Transaction [Line Items]
Preferred shares issued	5,239	4,900
Shares exchanged under securities purchase and exchange agreement	4,900
Number of shares retired	4,900

Operating Segments and Geogra_3

Operating Segments and Geographic Information - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2018SegmentCustomer	Dec. 31, 2017Customer
Segment Reporting Revenue Reconciling Item [Line Items]
Number of reportable segments | Segment	1
Number of customer in each individual country	5	4
Supplier agreement term	5 years
Sales [Member] | Customer Concentration [Member]
Segment Reporting Revenue Reconciling Item [Line Items]
Concentration risk percentage	100.00%	100.00%
Cost of Goods, Total [Member] | Supplier Concentration Risk [Member]
Segment Reporting Revenue Reconciling Item [Line Items]
Concentration risk percentage	100.00%
Maximum [Member]
Segment Reporting Revenue Reconciling Item [Line Items]
Number of customer in each individual country	4	4

Operating Segments and Geogra_4

Operating Segments and Geographic Information - Schedule of Revenues Generated from External Customers and Long-lived Assets by Area (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	$ 21	$ 14
Long Lived Assets	367	477
Canada [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues		1
Ireland [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues		14
Italy [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	1
The Netherlands [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues		(1)
Germany [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	20
U.S. [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Long Lived Assets	346	453
Foreign [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Long Lived Assets	$ 21	$ 24

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail)	Jun. 01, 2016	Jan. 02, 2016	Dec. 01, 2013	May 31, 2012	Dec. 31, 2017USD ($)Facility	Dec. 31, 2018USD ($)	Dec. 31, 2017USD ($)
Reorganization [Member] | Irvine [Member]
Commitments And Contingencies [Line Items]
Lease expiration period					Sep. 30, 2020
Number of facilities vacated | Facility					1
Fair value of remaining lease obligation					$ 222,000		$ 222,000
Vacated facility remaining lease term					33 months
Facility Leases [Member]
Commitments And Contingencies [Line Items]
Rent expense						$ 384,000	867,000
Facility Leases [Member] | California [Member]
Commitments And Contingencies [Line Items]
Lease period				5 years
Lease expiration period	May 31, 2022			May 31, 2017
Lease renewal term	5 years
Facility Leases [Member] | Ireland [Member]
Commitments And Contingencies [Line Items]
Lease period			1 year
Lease renewal term			1 month
Lease commencement date			Dec. 1, 2013
Facility Leases [Member] | The Netherlands [Member]
Commitments And Contingencies [Line Items]
Lease period		30 months
Lease commencement date		Jan. 1, 2016
Lease termination period		2018-02
Facility Leases [Member] | Reorganization [Member] | Irvine [Member]
Commitments And Contingencies [Line Items]
Number of facilities vacated | Facility					1
Fair value of remaining lease obligation					$ 222,000		$ 222,000
Vacated facility remaining lease term					33 months

Commitment and Contingencies -

Commitment and Contingencies - Annual Base Rental Cost Over the Term of the Leases (Detail) - Facility Leases [Member] $ in Thousands	Dec. 31, 2018USD ($)
Operating Leased Assets [Line Items]
2019	$ 292
2020	298
2021	287
2022	119
Total	$ 996

Income Taxes - Schedule of Prov

Income Taxes - Schedule of Provision for Income Taxes (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Current provision:
Federal	$ 0	$ 0
State	2	2
Foreign	(237)	243
Total current	(235)	245
Deferred provision
Federal	(1,103)	(3,335)
State	0	0
Foreign	(59)	(1,065)
Total deferred	(1,162)	(2,270)
Valuation allowance	1,162	2,270
Total deferred	0	0
Total income tax (benefit) provision	$ (235)	$ 245

Income Taxes - Schedule of Reco

Income Taxes - Schedule of Reconciliation of Federal Statutory Rate to Effective Rate (Detail)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Expected income tax benefit at federal statutory rate	21.00%	35.00%
State tax provision, net of federal benefit	0.00%	0.00%
Foreign rate differential	(8.10%)	(15.00%)
Nondeductible expenses	0.00%	(0.10%)
Foreign Tax	2.80%	(1.40%)
Change in valuation allowance	(13.50%)	(4.20%)
Effect of Change in Tax Rate	0.00%	(9.30%)
Other	0.60%	(6.50%)
Income tax provision (benefit)	2.70%	(1.40%)

Income Taxes - Components of De

Income Taxes - Components of Deferred Tax Assets (Detail) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Deferred tax assets:
Net operating loss carryforwards	$ 6,279	$ 5,019
Accrued expenses	47	31
Stock based compensation	0	0
Deferred tax assets	6,326	5,050
Valuation allowance	(6,310)	(5,033)
Net deferred tax assets	16	17
Deferred tax liabilities:
Depreciation	(16)	(17)
Total deferred tax liabilities	$ (16)	$ (17)

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Income Tax [Line Items]
Operating loss carryforwards	$ 16,300,000	$ 11,100,000
Operating loss carryforwards expiration year	2033
Operating Loss Carryforwards, Limitations on Use	NOL carryforwards may be limited in the event a cumulative change in ownership of 50% of certain shareholders occurs within a three year period
Federal tax at statutory rate	21.00%	35.00%
Unrecognized contingent liabilities	$ 0
Material tax related accrued interest and penalties	0	$ 0
State [Member]
Income Tax [Line Items]
Operating loss carryforwards	$ 600,000
Operating loss carryforwards expiration year	2028
U.S. Federal and State [Member]
Income Tax [Line Items]
Open tax years	2015 2016 2017 2018
Foreign Tax Authority [Member]
Income Tax [Line Items]
Open tax years	2014 2015 2016 2017 2018
Ireland [Member]
Income Tax [Line Items]
Operating loss carryforwards	$ 21,800,000	$ 21,500,000
Operating Loss Carryforwards, Limitations on Use	Under Irish rules, only such losses that occur within a three year period prior to commencing trading can be utilized to offset future trading taxable income.
Germany [Member]
Income Tax [Line Items]
Operating loss carryforwards	$ 800,000

Fourth Quarter 2017 Adjustmen_2

Fourth Quarter 2017 Adjustments - Additional Information (Detail) - Reorganization [Member]	Nov. 20, 2018USD ($)	Dec. 31, 2017USD ($)ft²FacilityEmployees	Dec. 31, 2017USD ($)	Dec. 31, 2018
Restructuring Cost And Reserve [Line Items]
Number of employees reduced | Employees		15
Percentage of employees reduced		38.50%
Reduction in operating expense		$ 1,078,000
Increase in tax provision expense		238,000
Compensation related adjustments		465,000	$ 465,000
Severance costs		332,000
Reversal of accrued incentive compensation costs		797,000	$ 797,000
Facilities related adjustments		357,000
Period to exercise vested options following termination			90 days
Terms and conditions for terminated employees awards vesting description				On the date of reorganization, the Company extended the terms and conditions for all equity grants for all terminated employees providing at least a one-year extension past the termination date for all vested stock options (Type I modification as prescribed by ASC Topic 718), and, in certain cases, the acceleration of unvested options or restricted share awards (Type III modification as prescribed by ASC Topic 718). For those terminated employees with RSU grants based on a market condition, the Company granted a one-year extension to vest according to the same market conditions as defined in the original grants. Generally, when a modification of an award occurs, the prior periods’ expense recognition associated with all unvested awards is reversed in the period of the modification on the basis that the old award is being exchanged for a new award.
Reduction of stock-based compensation expense			$ 1,350,000
Increase in fair value as stock-based compensation expense			380,000
Net reduction of stock-based compensation expense			970,000
Accrued Expense [Member]
Restructuring Cost And Reserve [Line Items]
Write-down of leasehold expenses		8,000
Furniture and Fixtures [Member]
Restructuring Cost And Reserve [Line Items]
Write-down of leasehold expenses		89,000
Engineering Tools, Molds and Fixtures [Member]
Restructuring Cost And Reserve [Line Items]
Write-down of leasehold expenses		$ 52,000
Irvine [Member]
Restructuring Cost And Reserve [Line Items]
Number of facilities vacated | Facility		1
Vacated facility lease area | ft²		8,500
Vacated facility remaining lease term		33 months
Vacated facility lease expiration period		Sep. 30, 2020
Fair value of remaining lease obligation		$ 222,000	222,000
Irish Tax Authorities [Member]
Restructuring Cost And Reserve [Line Items]
Tax reserve for unpaid withholding taxes		238,000	238,000
Withholding of income taxes to be paid		$ 238,000	$ 238,000
Unprompted voluntary disclosure settlment, net cost	$ 79,000